Screening Marine Natural Products for New Drug Leads against Trypanosomatids and Malaria
Neglected Tropical Diseases (NTD) represent a serious threat to humans, especially for those living in poor or developing countries. Almost one-sixth of the world population is at risk of suffering from these diseases and many thousands die because of NTDs, to which we should add the sanitary, labor...
Saved in:
| Published in | Marine drugs Vol. 18; no. 4; p. 187 |
|---|---|
| Main Authors | , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Switzerland
MDPI
31.03.2020
MDPI AG |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Neglected Tropical Diseases (NTD) represent a serious threat to humans, especially for those living in poor or developing countries. Almost one-sixth of the world population is at risk of suffering from these diseases and many thousands die because of NTDs, to which we should add the sanitary, labor and social issues that hinder the economic development of these countries. Protozoan-borne diseases are responsible for more than one million deaths every year. Visceral leishmaniasis, Chagas disease or sleeping sickness are among the most lethal NTDs. Despite not being considered an NTD by the World Health Organization (WHO), malaria must be added to this sinister group. Malaria, caused by the apicomplexan parasite Plasmodium falciparum, is responsible for thousands of deaths each year. The treatment of this disease has been losing effectiveness year after year. Many of the medicines currently in use are obsolete due to their gradual loss of efficacy, their intrinsic toxicity and the emergence of drug resistance or a lack of adherence to treatment. Therefore, there is an urgent and global need for new drugs. Despite this, the scant interest shown by most of the stakeholders involved in the pharmaceutical industry makes our present therapeutic arsenal scarce, and until recently, the search for new drugs has not been seriously addressed. The sources of new drugs for these and other pathologies include natural products, synthetic molecules or repurposing drugs. The most frequent sources of natural products are microorganisms, e.g., bacteria, fungi, yeasts, algae and plants, which are able to synthesize many drugs that are currently in use (e.g. antimicrobials, antitumor, immunosuppressants, etc.). The marine environment is another well-established source of bioactive natural products, with recent applications against parasites, bacteria and other pathogens which affect humans and animals. Drug discovery techniques have rapidly advanced since the beginning of the millennium. The combination of novel techniques that include the genetic modification of pathogens, bioimaging and robotics has given rise to the standardization of High-Performance Screening platforms in the discovery of drugs. These advancements have accelerated the discovery of new chemical entities with antiparasitic effects. This review presents critical updates regarding the use of High-Throughput Screening (HTS) in the discovery of drugs for NTDs transmitted by protozoa, including malaria, and its application in the discovery of new drugs of marine origin. |
|---|---|
| AbstractList | Neglected Tropical Diseases (NTD) represent a serious threat to humans, especially for those living in poor or developing countries. Almost one-sixth of the world population is at risk of suffering from these diseases and many thousands die because of NTDs, to which we should add the sanitary, labor and social issues that hinder the economic development of these countries. Protozoan-borne diseases are responsible for more than one million deaths every year. Visceral leishmaniasis, Chagas disease or sleeping sickness are among the most lethal NTDs. Despite not being considered an NTD by the World Health Organization (WHO), malaria must be added to this sinister group. Malaria, caused by the apicomplexan parasite
Plasmodium falciparum
, is responsible for thousands of deaths each year. The treatment of this disease has been losing effectiveness year after year. Many of the medicines currently in use are obsolete due to their gradual loss of efficacy, their intrinsic toxicity and the emergence of drug resistance or a lack of adherence to treatment. Therefore, there is an urgent and global need for new drugs. Despite this, the scant interest shown by most of the stakeholders involved in the pharmaceutical industry makes our present therapeutic arsenal scarce, and until recently, the search for new drugs has not been seriously addressed. The sources of new drugs for these and other pathologies include natural products, synthetic molecules or repurposing drugs. The most frequent sources of natural products are microorganisms, e.g., bacteria, fungi, yeasts, algae and plants, which are able to synthesize many drugs that are currently in use (e.g. antimicrobials, antitumor, immunosuppressants, etc.). The marine environment is another well-established source of bioactive natural products, with recent applications against parasites, bacteria and other pathogens which affect humans and animals. Drug discovery techniques have rapidly advanced since the beginning of the millennium. The combination of novel techniques that include the genetic modification of pathogens, bioimaging and robotics has given rise to the standardization of High-Performance Screening platforms in the discovery of drugs. These advancements have accelerated the discovery of new chemical entities with antiparasitic effects. This review presents critical updates regarding the use of High-Throughput Screening (HTS) in the discovery of drugs for NTDs transmitted by protozoa, including malaria, and its application in the discovery of new drugs of marine origin. Neglected Tropical Diseases (NTD) represent a serious threat to humans, especially for those living in poor or developing countries. Almost one-sixth of the world population is at risk of suffering from these diseases and many thousands die because of NTDs, to which we should add the sanitary, labor and social issues that hinder the economic development of these countries. Protozoan-borne diseases are responsible for more than one million deaths every year. Visceral leishmaniasis, Chagas disease or sleeping sickness are among the most lethal NTDs. Despite not being considered an NTD by the World Health Organization (WHO), malaria must be added to this sinister group. Malaria, caused by the apicomplexan parasite Plasmodium falciparum, is responsible for thousands of deaths each year. The treatment of this disease has been losing effectiveness year after year. Many of the medicines currently in use are obsolete due to their gradual loss of efficacy, their intrinsic toxicity and the emergence of drug resistance or a lack of adherence to treatment. Therefore, there is an urgent and global need for new drugs. Despite this, the scant interest shown by most of the stakeholders involved in the pharmaceutical industry makes our present therapeutic arsenal scarce, and until recently, the search for new drugs has not been seriously addressed. The sources of new drugs for these and other pathologies include natural products, synthetic molecules or repurposing drugs. The most frequent sources of natural products are microorganisms, e.g., bacteria, fungi, yeasts, algae and plants, which are able to synthesize many drugs that are currently in use (e.g. antimicrobials, antitumor, immunosuppressants, etc.). The marine environment is another well-established source of bioactive natural products, with recent applications against parasites, bacteria and other pathogens which affect humans and animals. Drug discovery techniques have rapidly advanced since the beginning of the millennium. The combination of novel techniques that include the genetic modification of pathogens, bioimaging and robotics has given rise to the standardization of High-Performance Screening platforms in the discovery of drugs. These advancements have accelerated the discovery of new chemical entities with antiparasitic effects. This review presents critical updates regarding the use of High-Throughput Screening (HTS) in the discovery of drugs for NTDs transmitted by protozoa, including malaria, and its application in the discovery of new drugs of marine origin. Neglected Tropical Diseases (NTD) represent a serious threat to humans, especially for those living in poor or developing countries. Almost one-sixth of the world population is at risk of suffering from these diseases and many thousands die because of NTDs, to which we should add the sanitary, labor and social issues that hinder the economic development of these countries. Protozoan-borne diseases are responsible for more than one million deaths every year. Visceral leishmaniasis, Chagas disease or sleeping sickness are among the most lethal NTDs. Despite not being considered an NTD by the World Health Organization (WHO), malaria must be added to this sinister group. Malaria, caused by the apicomplexan parasite Plasmodium falciparum, is responsible for thousands of deaths each year. The treatment of this disease has been losing effectiveness year after year. Many of the medicines currently in use are obsolete due to their gradual loss of efficacy, their intrinsic toxicity and the emergence of drug resistance or a lack of adherence to treatment. Therefore, there is an urgent and global need for new drugs. Despite this, the scant interest shown by most of the stakeholders involved in the pharmaceutical industry makes our present therapeutic arsenal scarce, and until recently, the search for new drugs has not been seriously addressed. The sources of new drugs for these and other pathologies include natural products, synthetic molecules or repurposing drugs. The most frequent sources of natural products are microorganisms, e.g., bacteria, fungi, yeasts, algae and plants, which are able to synthesize many drugs that are currently in use (e.g. antimicrobials, antitumor, immunosuppressants, etc.). The marine environment is another well-established source of bioactive natural products, with recent applications against parasites, bacteria and other pathogens which affect humans and animals. Drug discovery techniques have rapidly advanced since the beginning of the millennium. The combination of novel techniques that include the genetic modification of pathogens, bioimaging and robotics has given rise to the standardization of High-Performance Screening platforms in the discovery of drugs. These advancements have accelerated the discovery of new chemical entities with antiparasitic effects. This review presents critical updates regarding the use of High-Throughput Screening (HTS) in the discovery of drugs for NTDs transmitted by protozoa, including malaria, and its application in the discovery of new drugs of marine origin.Neglected Tropical Diseases (NTD) represent a serious threat to humans, especially for those living in poor or developing countries. Almost one-sixth of the world population is at risk of suffering from these diseases and many thousands die because of NTDs, to which we should add the sanitary, labor and social issues that hinder the economic development of these countries. Protozoan-borne diseases are responsible for more than one million deaths every year. Visceral leishmaniasis, Chagas disease or sleeping sickness are among the most lethal NTDs. Despite not being considered an NTD by the World Health Organization (WHO), malaria must be added to this sinister group. Malaria, caused by the apicomplexan parasite Plasmodium falciparum, is responsible for thousands of deaths each year. The treatment of this disease has been losing effectiveness year after year. Many of the medicines currently in use are obsolete due to their gradual loss of efficacy, their intrinsic toxicity and the emergence of drug resistance or a lack of adherence to treatment. Therefore, there is an urgent and global need for new drugs. Despite this, the scant interest shown by most of the stakeholders involved in the pharmaceutical industry makes our present therapeutic arsenal scarce, and until recently, the search for new drugs has not been seriously addressed. The sources of new drugs for these and other pathologies include natural products, synthetic molecules or repurposing drugs. The most frequent sources of natural products are microorganisms, e.g., bacteria, fungi, yeasts, algae and plants, which are able to synthesize many drugs that are currently in use (e.g. antimicrobials, antitumor, immunosuppressants, etc.). The marine environment is another well-established source of bioactive natural products, with recent applications against parasites, bacteria and other pathogens which affect humans and animals. Drug discovery techniques have rapidly advanced since the beginning of the millennium. The combination of novel techniques that include the genetic modification of pathogens, bioimaging and robotics has given rise to the standardization of High-Performance Screening platforms in the discovery of drugs. These advancements have accelerated the discovery of new chemical entities with antiparasitic effects. This review presents critical updates regarding the use of High-Throughput Screening (HTS) in the discovery of drugs for NTDs transmitted by protozoa, including malaria, and its application in the discovery of new drugs of marine origin. Neglected Tropical Diseases (NTD) represent a serious threat to humans, especially for those living in poor or developing countries. Almost one-sixth of the world population is at risk of suffering from these diseases and many thousands die because of NTDs, to which we should add the sanitary, labor and social issues that hinder the economic development of these countries. Protozoan-borne diseases are responsible for more than one million deaths every year. Visceral leishmaniasis, Chagas disease or sleeping sickness are among the most lethal NTDs. Despite not being considered an NTD by the World Health Organization (WHO), malaria must be added to this sinister group. Malaria, caused by the apicomplexan parasite , is responsible for thousands of deaths each year. The treatment of this disease has been losing effectiveness year after year. Many of the medicines currently in use are obsolete due to their gradual loss of efficacy, their intrinsic toxicity and the emergence of drug resistance or a lack of adherence to treatment. Therefore, there is an urgent and global need for new drugs. Despite this, the scant interest shown by most of the stakeholders involved in the pharmaceutical industry makes our present therapeutic arsenal scarce, and until recently, the search for new drugs has not been seriously addressed. The sources of new drugs for these and other pathologies include natural products, synthetic molecules or repurposing drugs. The most frequent sources of natural products are microorganisms, e.g., bacteria, fungi, yeasts, algae and plants, which are able to synthesize many drugs that are currently in use (e.g. antimicrobials, antitumor, immunosuppressants, etc.). The marine environment is another well-established source of bioactive natural products, with recent applications against parasites, bacteria and other pathogens which affect humans and animals. Drug discovery techniques have rapidly advanced since the beginning of the millennium. The combination of novel techniques that include the genetic modification of pathogens, bioimaging and robotics has given rise to the standardization of High-Performance Screening platforms in the discovery of drugs. These advancements have accelerated the discovery of new chemical entities with antiparasitic effects. This review presents critical updates regarding the use of High-Throughput Screening (HTS) in the discovery of drugs for NTDs transmitted by protozoa, including malaria, and its application in the discovery of new drugs of marine origin. |
| Author | Balaña-Fouce, Rafael Reguera, Rosa M. Álvarez-Bardón, María Ordóñez, César García-Estrada, Carlos Sepúlveda-Crespo, Daniel Pérez-Pertejo, Yolanda Carballeira, Nestor M. Tekwani, Babu L. Martinez-Valladares, Maria Murugesan, Sankaranarayanan |
| AuthorAffiliation | 3 Department of Infectious Diseases, Division of Drug Discovery, Southern Research, Birmingham, AL 35205, USA; btekwani@southernresearch.org 6 INBIOTEC (Instituto de Biotecnología de León), Avda. Real 1-Parque Científico de León, 24006 León, Spain; carlos.garcia@inbiotec.com 2 Department of Chemistry, University of Puerto Rico, Río Piedras 00925-2537, San Juan, Puerto Rico; nestor.carballeira1@upr.edu 1 Department of Biomedical Sciences; University of León, 24071 León, Spain; malvb@unileon.es (M.Á.-B.); myperp@unileon.es (Y.P.-P.); c.ordonez@unileon.es (C.O.); dsepc@unileon.es (D.S.-C.); rmregt@unileon.es (R.M.R.) 5 Department of Animal Health, Instituto de Ganadería de Montaña (CSIC-Universidad de León), Grulleros, 24346 León, Spain; mmarva@unileon.es 4 Department of Pharmacy, Birla Institute of Technology and Science, Pilani Campus, Vidya Vihar, Pilani 333031, India; murugesan@pilani.bits-pilani.ac.in |
| AuthorAffiliation_xml | – name: 6 INBIOTEC (Instituto de Biotecnología de León), Avda. Real 1-Parque Científico de León, 24006 León, Spain; carlos.garcia@inbiotec.com – name: 1 Department of Biomedical Sciences; University of León, 24071 León, Spain; malvb@unileon.es (M.Á.-B.); myperp@unileon.es (Y.P.-P.); c.ordonez@unileon.es (C.O.); dsepc@unileon.es (D.S.-C.); rmregt@unileon.es (R.M.R.) – name: 2 Department of Chemistry, University of Puerto Rico, Río Piedras 00925-2537, San Juan, Puerto Rico; nestor.carballeira1@upr.edu – name: 4 Department of Pharmacy, Birla Institute of Technology and Science, Pilani Campus, Vidya Vihar, Pilani 333031, India; murugesan@pilani.bits-pilani.ac.in – name: 5 Department of Animal Health, Instituto de Ganadería de Montaña (CSIC-Universidad de León), Grulleros, 24346 León, Spain; mmarva@unileon.es – name: 3 Department of Infectious Diseases, Division of Drug Discovery, Southern Research, Birmingham, AL 35205, USA; btekwani@southernresearch.org |
| Author_xml | – sequence: 1 givenname: María orcidid: 0000-0002-0930-0371 surname: Álvarez-Bardón fullname: Álvarez-Bardón, María – sequence: 2 givenname: Yolanda surname: Pérez-Pertejo fullname: Pérez-Pertejo, Yolanda – sequence: 3 givenname: César surname: Ordóñez fullname: Ordóñez, César – sequence: 4 givenname: Daniel orcidid: 0000-0002-8053-6045 surname: Sepúlveda-Crespo fullname: Sepúlveda-Crespo, Daniel – sequence: 5 givenname: Nestor M. surname: Carballeira fullname: Carballeira, Nestor M. – sequence: 6 givenname: Babu L. surname: Tekwani fullname: Tekwani, Babu L. – sequence: 7 givenname: Sankaranarayanan surname: Murugesan fullname: Murugesan, Sankaranarayanan – sequence: 8 givenname: Maria orcidid: 0000-0002-3723-1895 surname: Martinez-Valladares fullname: Martinez-Valladares, Maria – sequence: 9 givenname: Carlos surname: García-Estrada fullname: García-Estrada, Carlos – sequence: 10 givenname: Rosa M. surname: Reguera fullname: Reguera, Rosa M. – sequence: 11 givenname: Rafael orcidid: 0000-0003-0418-6116 surname: Balaña-Fouce fullname: Balaña-Fouce, Rafael |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32244488$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkVtrFTEUhYNU7EVf_AEyjyIcTSb3F0HqrXCsghV8C3uSzJgykxyTGaX_3oyn1lZ8SthZ-dZK1jE6iCl6hB4T_JxSjV9MjijMMFHyHjoiQuBNHcuDW_tDdFzKJcaUK80eoEPatowxpY7Q1882ex9DHJoPkEP0zTnMS4ax-ZSTW-xcmj7l5tz_bF7nZWi2HlxpYIAQy9xc5KsdxFTSBHNY59FVzFhB8BDd72Es_tH1eoK-vH1zcfp-s_347uz01XZjOcHzRjropOu0ZJJb5jXhRBGMZS-l6i2xPRcaK2H7FjqLqRJKU0u7FnMrrXCanqCzPdcluDS7HCbIVyZBML8HKQ8G8hzs6A3nQgFgob0TTBMMveyo8MRp1oHjpLJe7lm7pZu8sz7O9SfuQO-exPDNDOmHkS2tIdcwT68BOX1ffJnNFIr14wjRp6WYtj6gVbJVq9eT2143Jn-qqYJne4HNqZTs-xsJwWbt3fztvYrxP2Ib5tpJWnOG8X9XfgH5aq-G |
| CitedBy_id | crossref_primary_10_3390_pharmaceutics13081255 crossref_primary_10_1039_D0MD00353K crossref_primary_10_1016_j_algal_2023_103241 crossref_primary_10_1136_bmjopen_2021_052897 crossref_primary_10_3390_molecules25225483 crossref_primary_10_1039_D0NP00078G crossref_primary_10_3390_molecules26051388 crossref_primary_10_3233_JCB_209010 crossref_primary_10_1080_07391102_2021_1970025 crossref_primary_10_3390_md19040179 crossref_primary_10_3389_fcimb_2021_797509 crossref_primary_10_3389_fphar_2023_1233253 crossref_primary_10_3390_life14060684 crossref_primary_10_3390_md22070309 crossref_primary_10_3390_molecules29174041 crossref_primary_10_1080_1062936X_2023_2251876 crossref_primary_10_3390_biom11030460 crossref_primary_10_3389_fphar_2022_841941 crossref_primary_10_1021_acsomega_2c03395 crossref_primary_10_3389_fmicb_2023_1285902 crossref_primary_10_1186_s12982_024_00247_1 crossref_primary_10_3390_biomedicines12010213 crossref_primary_10_1002_bip_23398 crossref_primary_10_3390_md20100587 crossref_primary_10_3390_molecules26185676 crossref_primary_10_3390_ph16050657 crossref_primary_10_1016_j_crmicr_2024_100304 crossref_primary_10_3390_futurepharmacol4010015 crossref_primary_10_3390_md19110637 crossref_primary_10_1155_2024_5924799 crossref_primary_10_1186_s40249_021_00796_6 crossref_primary_10_3390_molecules25235704 crossref_primary_10_3390_md21060333 crossref_primary_10_1016_j_exppara_2023_108554 crossref_primary_10_1039_D2NP00027J |
| Cites_doi | 10.1016/j.idc.2012.03.005 10.1016/S1470-2045(00)00292-8 10.1016/j.ijpddr.2014.07.006 10.1021/acschembio.8b00389 10.1002/cyto.a.23927 10.1111/j.1471-4159.2008.05706.x 10.1016/j.bmc.2006.02.026 10.1186/1475-2875-12-58 10.1016/S1473-3099(07)70209-8 10.1002/med.21486 10.1038/nbt.2289 10.1016/S0140-6736(15)01283-0 10.1016/j.jneuroim.2003.08.033 10.3390/md17010019 10.1016/j.molbiopara.2013.02.005 10.1016/S0140-6736(09)61117-X 10.1371/journal.pntd.0000962 10.1016/j.idc.2018.10.003 10.1515/pac-2018-1102 10.1124/pr.115.011411 10.1128/AAC.01949-15 10.1016/j.ijpddr.2011.12.002 10.1016/j.drudis.2014.09.012 10.1016/j.actatropica.2017.07.004 10.1371/journal.pntd.0002475 10.1016/0140-6736(92)92180-N 10.3390/ijerph7124267 10.2174/1386207053328101 10.1080/17512433.2018.1509704 10.1177/1087057114555846 10.1021/jm0010724 10.1371/journal.pntd.0000303 10.1371/journal.pntd.0001691 10.1046/j.1365-3156.2001.00710.x 10.1186/1471-2121-10-45 10.1038/srep16414 10.4062/biomolther.2016.067 10.1186/s12936-019-2661-x 10.1016/j.parint.2013.07.011 10.1016/j.bmc.2010.08.055 10.1016/j.pt.2018.07.001 10.1128/AAC.00246-11 10.2174/1381612823666170601101644 10.1128/CMR.00048-18 10.2147/DDDT.S61443 10.1128/AAC.04684-14 10.1128/AAC.50.4.1586-1589.2006 10.1016/S0140-6736(19)31139-0 10.1038/nrmicro.2016.193 10.1016/j.cmi.2017.04.013 10.1159/000109767 10.1017/S0031182017002116 10.1186/1756-3305-7-89 10.1093/jac/dkt165 10.1371/journal.pone.0067441 10.1016/j.bmcl.2014.07.050 10.1086/512241 10.2174/1389557023405549 10.1016/S0140-6736(15)60395-6 10.3389/fphar.2017.00754 10.12968/hmed.2016.77.10.C157 10.1371/journal.pntd.0003666 10.1007/s10741-010-9211-5 10.1179/2047773215Y.0000000013 10.1371/journal.pntd.0001787 10.1021/acsinfecdis.5b00143 10.1074/jbc.M501100200 10.1021/ja00280a055 10.1016/j.molbiopara.2004.04.006 10.1086/429929 10.1128/AAC.44.6.1645-1649.2000 10.2165/00002018-200730060-00003 10.1016/j.idc.2018.10.015 10.1016/j.actatropica.2015.12.017 10.1111/j.1574-6976.2010.00252.x 10.3390/molecules19067869 10.1016/S0140-6736(17)32758-7 10.3390/md14090163 10.1016/S0140-6736(17)31510-6 10.1002/cmdc.201500301 10.1186/s12936-018-2265-x 10.1016/j.pt.2013.12.004 10.1038/nrd4683 10.1074/jbc.274.27.19383 10.1021/acs.jmedchem.8b01161 10.1016/S1473-3099(03)00517-6 10.3390/md11030599 10.1172/JCI115678 10.1016/j.exppara.2017.01.002 10.1177/1087057114550585 10.1038/nrmicro3097 10.1021/jm201091t 10.1016/S1413-8670(10)70084-2 10.1128/AAC.01129-16 10.1093/jac/dkq502 10.3390/md18010005 10.1016/S0035-9203(02)90044-1 10.1016/S0140-6736(17)31612-4 10.1016/j.drudis.2014.06.010 10.1016/j.vetpar.2016.07.011 10.1177/2472555218796410 10.2165/00003495-199345030-00009 10.1038/nrd4457 10.1093/jac/dks275 10.1186/1471-2334-12-1 10.3390/md8010047 10.1128/AAC.00431-10 10.1093/jac/dkp206 10.1016/j.chemphyslip.2010.11.006 10.1002/med.21377 10.1128/EC.2.5.1003-1008.2003 10.1021/acs.jmedchem.5b01699 10.1021/np100348x 10.1038/nm.3073 10.2144/03355rr02 10.2165/00003088-199019040-00002 10.1016/j.pt.2009.06.006 10.1080/08982104.2017.1380664 10.1021/jm030475b 10.1126/science.6775372 10.1038/sj.bjp.0707354 10.1074/jbc.M005423200 10.1021/acs.jcim.7b00072 10.3390/md17030192 10.1016/j.ijpddr.2019.11.004 10.1517/14740338.2013.827168 10.3390/medsci6010012 10.1056/NEJMoa0903627 10.1056/NEJMra1410150 10.1007/s40265-018-0911-9 10.1007/s00436-017-5477-z 10.1016/j.jiph.2014.04.007 10.1186/1475-2875-10-263 10.1021/jm400362b 10.1016/S0166-6851(02)00096-8 10.1128/AAC.00887-13 10.1089/adt.2011.0378 10.2174/156802611796575894 10.1016/j.ijpddr.2014.05.001 10.1016/j.chom.2013.06.005 10.1111/j.1365-2958.2009.06761.x 10.1177/2472555218823171 10.3390/md9102131 10.1128/AAC.01370-08 10.1007/s00436-008-1154-6 10.1517/14656566.2013.755515 10.1002/ardp.201700373 10.1016/j.molbiopara.2013.02.008 10.1016/j.ijpddr.2018.04.007 10.3390/md8112733 10.1016/j.pt.2014.04.003 10.1074/jbc.R500031200 10.1016/j.bjp.2014.07.001 10.1371/journal.pntd.0005635 10.1016/j.bioorg.2019.103276 10.1111/ajt.12340 10.1016/j.tetlet.2010.09.083 10.1128/AAC.00499-12 10.1073/pnas.0711014105 10.1055/s-0030-1250526 10.1007/s11745-015-4114-9 10.1093/infdis/jir037 10.1002/jnr.490210109 10.1371/journal.pntd.0004118 10.1002/j.1552-4604.1986.tb02897.x 10.1021/cr500098f 10.1016/S0020-7519(02)00194-7 10.1007/978-1-4939-6960-9_9 10.1191/0960327106het653oa 10.1016/j.ijpddr.2012.01.003 10.1056/NEJMoa066536 10.1016/j.chemphyslip.2013.05.002 10.1128/AAC.01401-12 10.1016/j.molbiopara.2006.11.013 10.1016/j.exppara.2008.05.003 10.1159/000252658 10.1111/j.1365-2958.2008.06305.x 10.1016/j.jaad.2014.08.051 10.1007/s00418-014-1250-x 10.1016/j.ejim.2017.09.022 10.1021/np800163u 10.1016/j.drudis.2017.06.004 10.1080/14656566.2019.1650915 10.1002/j.1460-2075.1987.tb04741.x 10.4155/fmc.12.188 10.1371/journal.pone.0014275 10.1128/AAC.49.9.3776-3783.2005 10.1186/1475-2875-8-294 10.1016/S0140-6736(18)31204-2 10.1128/AAC.00709-12 10.1017/S0031182016002031 10.1021/cb500981y 10.1099/00221287-70-3-491 10.1128/AAC.48.8.3010-3015.2004 10.1016/j.ejmech.2014.07.006 10.1080/14760584.2016.1236689 10.1056/NEJMoa1313122 10.3390/md7020130 10.1080/20477724.2015.1133033 10.1016/j.trstmh.2008.01.021 10.1038/s41467-018-04221-9 10.1007/978-1-4939-7847-2_3 10.1177/1087057116673796 10.1021/cr500546h 10.1002/cmdc.201100344 10.1089/adt.2015.652 10.1021/acsinfecdis.7b00197 10.3390/md15110323 10.1038/srep08771 10.1016/j.drudis.2019.03.007 10.1016/j.coph.2018.05.006 10.1042/bse0510063 10.1126/science.aat9446 10.4269/ajtmh.19-0310 10.1002/14651858.CD006201.pub3 10.1016/S0140-6736(03)15162-8 10.1186/s12936-017-1805-0 10.1016/S0140-6736(96)06217-4 10.1016/B978-0-12-385863-4.00004-6 10.1016/j.chembiol.2012.01.004 10.1016/j.pt.2016.04.014 10.12688/f1000research.11120.1 10.1016/j.pt.2009.07.006 10.1016/S0166-6851(00)00195-X 10.1186/s12936-017-2151-y 10.1007/s40265-019-1051-6 10.1517/14656566.2016.1146683 10.1039/c3np70052f 10.1016/j.pt.2007.08.019 10.1159/isbn.978-3-318-00599-8 10.1016/S0166-6851(00)00270-X 10.4269/ajtmh.2007.77.89 10.1128/AAC.34.2.183 10.1016/j.meegid.2018.01.011 10.1038/clpt.2012.236 10.1371/journal.pone.0138528 10.1017/S0031182010001137 10.4062/biomolther.2016.181 10.1126/science.285.5425.242 10.1007/s11427-015-4948-7 10.1056/NEJM199912093412403 10.1039/C0OB00326C 10.1186/s40249-019-0550-8 10.1016/j.actatropica.2019.105173 10.1016/j.pt.2018.08.006 10.1128/AAC.00870-13 10.1371/journal.pone.0105817 10.1055/s-0034-1382374 10.1093/cid/cix807 10.1371/journal.pntd.0000509 10.1128/AAC.01912-16 10.3390/md9112369 10.1016/j.chom.2015.12.001 10.1016/S1473-3099(16)30140-2 10.1016/j.actatropica.2019.105107 10.1016/S1473-3099(17)30538-8 10.4269/ajtmh.16-0761 10.1016/j.actatropica.2011.12.010 10.1126/science.aau1682 10.1039/C5NP00156K 10.1016/j.ijpddr.2015.04.002 10.1128/AAC.48.5.1807-1810.2004 10.1016/j.pt.2017.12.002 10.4269/ajtmh.1996.55.586 10.1016/S0140-6736(13)60024-0 10.1016/S1473-3099(16)30328-0 10.3390/molecules200712459 10.3390/tropicalmed2030036 10.1073/pnas.86.8.2607 10.1007/s00436-002-0766-5 10.1074/jbc.M211391200 10.1590/0074-02760140405 10.1371/journal.pntd.0000252 10.1186/s12936-019-2724-z 10.1038/nrd.2017.111 10.3390/md17060329 10.1371/journal.pntd.0007133 10.1016/S0140-6736(16)30171-4 10.1038/s41467-018-05777-2 10.1371/journal.pntd.0000720 10.1016/j.phytol.2014.12.019 10.1093/jac/dkv493 10.4155/fmc-2018-0512 10.1111/j.1462-5822.2011.01593.x 10.1093/jtm/tay110 10.1371/journal.pone.0035671 10.1016/S1473-3099(18)30309-8 10.4155/fmc-2017-0250 10.1371/journal.pntd.0002907 10.1016/j.bmcl.2012.08.019 10.1016/j.pt.2018.04.002 10.1111/pim.12431 10.1016/j.ijpddr.2019.06.003 10.1007/s40265-016-0538-7 10.1093/jac/dkt262 10.1038/s41586-018-0356-z 10.1021/jo00302a007 10.1016/S1474-4422(12)70296-X 10.1007/s40265-017-0705-5 10.1126/science.271.5246.219 10.3390/md11103661 10.1042/bst0310411 10.1128/AAC.00527-15 10.3390/md16080279 10.1016/j.bbrc.2005.10.121 10.1371/journal.ppat.1005436 10.1093/infdis/jis184 10.1007/s11745-009-3345-z 10.1371/journal.pntd.0006890 10.3390/molecules14072317 10.1038/clpt.1981.150 10.1093/jac/49.suppl_1.37 10.1200/JCO.2015.62.4734 |
| ContentType | Journal Article |
| Copyright | 2020 by the authors. 2020 |
| Copyright_xml | – notice: 2020 by the authors. 2020 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
| DOI | 10.3390/md18040187 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals (DOAJ) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1660-3397 |
| ExternalDocumentID | oai_doaj_org_article_5568aa069ed64910af7b36e1d94bad51 PMC7230869 32244488 10_3390_md18040187 |
| Genre | Journal Article Review |
| GrantInformation_xml | – fundername: Ministerio de Economía y Competitividad grantid: AGL2016-79813-C2-1R – fundername: Ministerio de Economía y Competitividad grantid: SAF2017-83575-R – fundername: Consejería de Educación, Junta de Castilla y León grantid: LE020P17 – fundername: Ministerio de Economía y Competitividad grantid: RYC-2015-18368 |
| GroupedDBID | --- 29M 2WC 53G 5GY 5VS 7X7 88E 8CJ 8FE 8FH 8FI 8FJ AADQD AAHBH AAYXX ABUWG ACGFO ACIHN ACPRK ADBBV AEAQA AENEX AEUYN AFKRA AFRAH AFZYC AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BBNVY BCNDV BENPR BHPHI BKSAR BPHCQ BVXVI CCPQU CITATION CS3 D1J DIK DU5 E3Z EBD EDH F5P FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IAO IHR ITC KQ8 LK5 LK8 M1P M48 M7P M7R MK0 MODMG M~E O5R O5S OK1 OVT P2P PCBAR PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RNS RPM TR2 UKHRP XSB CGR CUY CVF ECM EIF NPM PJZUB PPXIY PQGLB 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c510t-7dab7db97475c4e915181007f778fc1cf569086cf2abc0386893c3b205c7c6d93 |
| IEDL.DBID | M48 |
| ISSN | 1660-3397 |
| IngestDate | Wed Aug 27 01:30:33 EDT 2025 Thu Aug 21 18:08:20 EDT 2025 Mon Jul 21 11:27:14 EDT 2025 Mon Jul 21 05:49:56 EDT 2025 Tue Jul 01 03:19:40 EDT 2025 Thu Apr 24 22:56:46 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | trypanosomatids marine pharmacology neglected tropical diseases high-throughput screening target-based screening chloroquine derivatives phenotypic screening malaria |
| Language | English |
| License | https://creativecommons.org/licenses/by/4.0 Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c510t-7dab7db97475c4e915181007f778fc1cf569086cf2abc0386893c3b205c7c6d93 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0003-0418-6116 0000-0002-0930-0371 0000-0002-3723-1895 0000-0002-8053-6045 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3390/md18040187 |
| PMID | 32244488 |
| PQID | 2386287281 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_5568aa069ed64910af7b36e1d94bad51 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7230869 proquest_miscellaneous_2386287281 pubmed_primary_32244488 crossref_primary_10_3390_md18040187 crossref_citationtrail_10_3390_md18040187 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20200331 |
| PublicationDateYYYYMMDD | 2020-03-31 |
| PublicationDate_xml | – month: 3 year: 2020 text: 20200331 day: 31 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland |
| PublicationTitle | Marine drugs |
| PublicationTitleAlternate | Mar Drugs |
| PublicationYear | 2020 |
| Publisher | MDPI MDPI AG |
| Publisher_xml | – name: MDPI – name: MDPI AG |
| References | Varela (ref_172) 2017; 57 Cheruiyot (ref_250) 2016; 60 ref_258 ref_136 Baird (ref_158) 2018; 25 ref_259 Baker (ref_87) 2018; 34 Frame (ref_231) 2015; 10 Moffat (ref_170) 2017; 16 Haberland (ref_31) 2012; 17 Zulfiqar (ref_174) 2017; 22 Haegele (ref_82) 1981; 30 Anjum (ref_299) 2016; 24 ref_133 Price (ref_184) 2003; 278 Barrett (ref_64) 2007; 152 Carballeira (ref_322) 2012; 22 Stone (ref_122) 2016; 76 Teixeira (ref_194) 2018; 2018 Sun (ref_276) 2017; 16 Mohebali (ref_51) 2019; 200 Fairlamb (ref_73) 1989; 86 Buchholz (ref_272) 2011; 203 Guiguemde (ref_228) 2012; 19 Vandoolaeghe (ref_53) 2016; 15 Ebstie (ref_156) 2016; 10 Spinks (ref_186) 2015; 10 Shilabin (ref_304) 2008; 71 Regalado (ref_315) 2010; 73 Bacchi (ref_80) 1980; 210 Delves (ref_274) 2015; 59 Field (ref_225) 2017; 15 Carballeira (ref_324) 2016; 51 Frearson (ref_175) 2007; 23 Fuente (ref_232) 2018; 8 Annang (ref_167) 2015; 20 Filho (ref_296) 2010; 8 Wilkinson (ref_105) 2008; 105 Redondo (ref_195) 2006; 15-16 Kagami (ref_190) 2019; 11 Carballeira (ref_327) 2014; 24 Brajtburg (ref_121) 1990; 34 Cao (ref_309) 2005; 338 (ref_30) 2017; 23 Deeks (ref_90) 2019; 79 Noubiap (ref_149) 2014; 7 Tanaka (ref_265) 2013; 188 Diro (ref_42) 2012; 26 Nambati (ref_243) 2018; 17 Silvestrini (ref_264) 2013; 68 ref_70 Medhi (ref_146) 2009; 84 Lucantoni (ref_262) 2016; 60 Swinney (ref_171) 2013; 93 Matovu (ref_75) 2003; 2 Sundar (ref_119) 2010; 7 Pegg (ref_85) 2006; 281 Pescher (ref_217) 2011; 13 Jha (ref_126) 1999; 341 ref_76 ref_275 Reithinger (ref_40) 2007; 7 Kaiser (ref_108) 2011; 55 Skropeta (ref_308) 2011; 9 Vickers (ref_187) 2011; 51 Diro (ref_135) 2018; 66 Dube (ref_204) 2009; 25 Palmer (ref_153) 1993; 45 Sardinha (ref_160) 2010; 14 ref_83 Rinerhart (ref_9) 1990; 55 Patterson (ref_96) 2014; 30 Reguera (ref_61) 2007; 152 Alves (ref_110) 2018; 31 Cully (ref_227) 2014; 13 (ref_278) 2013; 11 Tasdemir (ref_326) 2010; 18 Laurens (ref_54) 2019; 22 Sales (ref_104) 2017; 97 Gego (ref_281) 2006; 50 Lindequist (ref_1) 2016; 24 Antinori (ref_33) 2018; 48 Castro (ref_107) 2006; 25 ref_88 ref_144 ref_143 Caridha (ref_247) 2019; 18 Bottieau (ref_19) 2019; 3 Priotto (ref_89) 2009; 374 Yousaf (ref_303) 2004; 47 Sienkiewicz (ref_188) 2008; 69 Peniche (ref_222) 2014; 58 Pal (ref_68) 2002; 122 Reguera (ref_111) 2019; 91 Roy (ref_208) 2000; 110 Henrich (ref_165) 2013; 30 Markowicz (ref_173) 2012; 13 ref_214 Camarda (ref_271) 2016; 71 ref_216 Xie (ref_235) 2018; 61 Klohe (ref_16) 2019; 8 Bakshi (ref_196) 2004; 136 ref_215 Casapia (ref_238) 2018; 18 Molyneux (ref_12) 2017; 389 Ashutosh (ref_211) 2005; 49 Milord (ref_86) 1992; 340 Ashley (ref_150) 2018; 78 Lucantoni (ref_268) 2015; 5 Collins (ref_66) 1986; 26 Hovlid (ref_226) 2016; 32 Martin (ref_277) 2012; 205 Fujii (ref_297) 2011; 77 Carlier (ref_36) 2015; 110 Schmid (ref_71) 2005; 191 Vigliano (ref_101) 2017; 174 ref_206 Gupta (ref_261) 2018; 38 Molina (ref_26) 2018; 391 Sinclair (ref_145) 2009; 8 Cui (ref_246) 2008; 120 Goupil (ref_55) 2014; 114 Ulrich (ref_115) 2001; 276 Peters (ref_163) 2007; 30 Katsuno (ref_224) 2015; 14 Senter (ref_6) 2012; 30 Schultzberg (ref_67) 1988; 21 Thornburg (ref_166) 2018; 13 Joanny (ref_242) 2012; 56 Schwartsmann (ref_11) 2001; 2 Burri (ref_79) 2003; 90 Kratz (ref_93) 2019; 198 Hoelz (ref_236) 2018; 10 Hedley (ref_57) 2016; 77 Handler (ref_41) 2015; 73 Sundar (ref_116) 2012; 14 Su (ref_139) 2015; 58 Persson (ref_177) 2003; 31 Thambo (ref_106) 1992; 42 Fattorusso (ref_310) 2009; 7 Ribeiro (ref_94) 2019; 12 Somsak (ref_254) 2012; 122 Wright (ref_311) 2011; 9 Adam (ref_161) 2018; 17 Tiwari (ref_192) 2018; 351 Morris (ref_140) 2011; 10 Alam (ref_233) 2019; 365 Attioua (ref_291) 2013; 11 Arias (ref_253) 2017; 116 Ang (ref_302) 2000; 44 ref_229 Torres (ref_286) 2014; 24 Reguera (ref_168) 2014; 4 ref_100 ref_221 ref_223 Prada (ref_197) 2012; 56 Pollastri (ref_91) 2018; 34 Bucknera (ref_179) 2012; 2 Co (ref_251) 2009; 53 Loo (ref_120) 2013; 12 Verma (ref_127) 2004; 48 Moraes (ref_189) 2019; 24 Paulino (ref_193) 2017; 17 Huprikar (ref_35) 2013; 13 Deray (ref_125) 2002; 49 Leidenberger (ref_248) 2017; 1601 Rason (ref_249) 2008; 102 ref_13 Mbui (ref_131) 2019; 68 Alkadi (ref_152) 2007; 53 Pandey (ref_141) 1999; 274 Cunningham (ref_316) 1972; 70 Carballeira (ref_318) 2009; 44 Wells (ref_239) 2018; 42 Ashok (ref_306) 2015; 97 ref_18 Singh (ref_218) 2009; 64 Jensen (ref_124) 2017; 27 Karl (ref_252) 2009; 8 Wyllie (ref_183) 2018; 560 Qian (ref_14) 2016; 16 Perry (ref_117) 2015; 385 Kar (ref_298) 2011; 66 Yang (ref_60) 2016; 60 Laurent (ref_234) 2006; 14 Wierenga (ref_69) 1987; 6 Hyde (ref_162) 2013; 188 Cleghorn (ref_182) 2011; 6 ref_25 Melaku (ref_137) 2007; 77 Lucantoni (ref_269) 2013; 57 ref_23 Lucantoni (ref_273) 2012; 4 ref_22 ref_21 ref_20 Rishikesh (ref_159) 2016; 110 Carballeira (ref_325) 2013; 11 Aseyev (ref_7) 2016; 17 Doua (ref_58) 1996; 55 Blunt (ref_3) 2016; 33 Reguera (ref_319) 2014; 4 Angheben (ref_34) 2015; 13 Meshnick (ref_142) 2002; 32 Reguera (ref_52) 2016; 227 Blum (ref_78) 2001; 6 Sakai (ref_301) 1986; 108 Delves (ref_267) 2018; 9 Dorlo (ref_129) 2012; 67 Burza (ref_38) 2018; 392 Graf (ref_77) 2015; 5 Sifaoui (ref_295) 2019; 92 Baldwin (ref_237) 2005; 280 Thompson (ref_109) 2016; 59 Sundar (ref_130) 2018; 145 Lepesheva (ref_178) 2011; 75 Mukhopadhyay (ref_118) 2014; 30 Roberts (ref_176) 2017; 23 Chatelain (ref_198) 2015; 20 Bennett (ref_255) 2004; 48 Brand (ref_185) 2012; 55 Crouzols (ref_207) 2018; 63 Njoroge (ref_56) 2014; 114 Bacchi (ref_81) 2002; 2 Witowski (ref_313) 2014; 80 ref_307 Sanderson (ref_84) 2008; 107 Britta (ref_288) 2011; 9 Pinazo (ref_102) 2013; 57 ref_300 Kumaratilake (ref_317) 1992; 89 Thao (ref_330) 2015; 20 Demicheli (ref_113) 2009; 14 Molina (ref_99) 2017; 61 Che (ref_256) 2012; 10 Jabari (ref_32) 2014; 142 Migotto (ref_331) 2008; 103 Imwong (ref_157) 2007; 195 ref_50 Sullivan (ref_147) 1996; 271 Orhan (ref_314) 2010; 8 ref_293 Xiao (ref_164) 2016; 36 Zijlstra (ref_43) 2003; 3 Andreu (ref_201) 2011; 35 Maser (ref_74) 1999; 285 Becerra (ref_294) 2015; 11 Kato (ref_260) 2018; 1787 Olliaro (ref_154) 1996; 348 Wilkinson (ref_97) 2011; 11 Lucumi (ref_257) 2010; 54 Delves (ref_263) 2018; 34 Lejon (ref_59) 2003; 144 Caldas (ref_98) 2019; 20 White (ref_15) 2014; 383 Cecchi (ref_17) 2017; 390 Tse (ref_138) 2019; 18 Gilbert (ref_169) 2013; 56 Scott (ref_5) 2017; 77 ref_283 Reguera (ref_200) 2015; 20 ref_285 Burri (ref_65) 2010; 137 Thao (ref_329) 2014; 19 Hasenkamp (ref_244) 2013; 12 ref_287 ref_63 ref_289 ref_62 Swann (ref_245) 2016; 2 Sinha (ref_241) 2017; 8 Gangadhar (ref_292) 2017; 174 ref_290 Kratz (ref_95) 2018; 11 Lang (ref_202) 2009; 25 Torrico (ref_181) 2018; 18 Salih (ref_114) 2017; 39 Mottram (ref_209) 2000; 107 Bermudez (ref_103) 2016; 156 Ashok (ref_305) 2014; 19 Sundar (ref_132) 2007; 3 Chatelain (ref_199) 2012; 2 Kennedy (ref_24) 2013; 12 Goyard (ref_212) 2014; 63 March (ref_282) 2013; 14 Echeverria (ref_27) 2019; 33 Chawla (ref_8) 2016; 387 Hendrickx (ref_47) 2018; 145 Sundar (ref_134) 2007; 356 Reguera (ref_220) 2019; 24 Wright (ref_312) 2001; 44 Bern (ref_28) 2015; 373 Karbwang (ref_151) 1990; 19 Spicer (ref_266) 2019; 24 Molina (ref_180) 2014; 370 Carballeira (ref_323) 2013; 172 Tekwani (ref_148) 2005; 8 Dagley (ref_219) 2015; 13 Meister (ref_284) 2018; 362 Manzano (ref_205) 2015; 5 Carballeira (ref_320) 2011; 164 Sundar (ref_123) 2010; 362 Backman (ref_155) 2015; 68 Vu (ref_230) 2018; 4 Colmenares (ref_39) 2002; 96 Esmenjaud (ref_37) 2017; 6 Fairlamb (ref_72) 2018; 34 Henriques (ref_213) 2014; 7 Feachem (ref_49) 2019; 394 Choy (ref_210) 2003; 35 Miller (ref_240) 2013; 19 ref_45 Wyllie (ref_191) 2009; 74 ref_44 Ghosh (ref_128) 2013; 68 Demetri (ref_10) 2016; 34 Singh (ref_46) 2016; 16 Yang (ref_203) 2017; 22 Mayer (ref_328) 2019; 18 Mesu (ref_92) 2018; 391 ref_2 Carballeira (ref_321) 2010; 51 Gunter (ref_29) 2020; 102 ref_48 Caridha (ref_112) 2019; 11 Campo (ref_280) 2015; 109 ref_4 Plouffe (ref_270) 2016; 19 Roth (ref_279) 2018; 9 |
| References_xml | – volume: 15-16 start-page: 733 year: 2006 ident: ref_195 article-title: Targeting atypical trypanosomatid DNA topoisomerase I publication-title: Drug Discov. Today – volume: 26 start-page: 309 year: 2012 ident: ref_42 article-title: Visceral leishmaniasis publication-title: Infect. Dis. Clin. North Am. doi: 10.1016/j.idc.2012.03.005 – volume: 2 start-page: 221 year: 2001 ident: ref_11 article-title: Marine organisms as a source of new anticancer agents publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(00)00292-8 – volume: 4 start-page: 326 year: 2014 ident: ref_319 article-title: Trypanosomatids topoisomerase re-visited. New structural findings and role in drug discovery publication-title: Int. J. Parasitol. Drugs Drug. Resist. doi: 10.1016/j.ijpddr.2014.07.006 – volume: 13 start-page: 2484 year: 2018 ident: ref_166 article-title: NCI Program for natural product discovery: A publicly-accessible library of natural product fractions for high-throughput screening publication-title: ACS Chem. Biol. doi: 10.1021/acschembio.8b00389 – ident: ref_229 doi: 10.1002/cyto.a.23927 – volume: 107 start-page: 1136 year: 2008 ident: ref_84 article-title: The blood–brain barrier significantly limits eflornithine entry into Trypanosoma brucei brucei infected mouse brain publication-title: J. Neurochem. doi: 10.1111/j.1471-4159.2008.05706.x – volume: 14 start-page: 4477 year: 2006 ident: ref_234 article-title: Antimalarial potential of xestoquinone, a protein kinase inhibitor isolated from a Vanuatu marine sponge Xestospongia sp. publication-title: Bioorg. Med. Chem. doi: 10.1016/j.bmc.2006.02.026 – volume: 12 start-page: 58 year: 2013 ident: ref_244 article-title: Evaluation of bioluminescence-based assays of anti-malarial drug activity publication-title: Malar. J. doi: 10.1186/1475-2875-12-58 – volume: 7 start-page: 581 year: 2007 ident: ref_40 article-title: Cutaneous leishmaniasis publication-title: Lancet Infect. Dis. doi: 10.1016/S1473-3099(07)70209-8 – volume: 38 start-page: 1511 year: 2018 ident: ref_261 article-title: Multistage inhibitors of the malaria parasite: Emerging hope for chemoprotection and malaria eradication publication-title: Med. Res. Rev. doi: 10.1002/med.21486 – volume: 30 start-page: 631 year: 2012 ident: ref_6 article-title: The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma publication-title: Nat. Biotechnol. doi: 10.1038/nbt.2289 – volume: 387 start-page: 1629 year: 2016 ident: ref_8 article-title: Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: A randomised, open–label, multicentre, phase 3 trial publication-title: Lancet doi: 10.1016/S0140-6736(15)01283-0 – volume: 144 start-page: 132 year: 2003 ident: ref_59 article-title: Neuro-inflammatory risk factors for treatment failure in “early second stage” sleeping sickness patients treated with pentamidine publication-title: J. Neuroimmunol. doi: 10.1016/j.jneuroim.2003.08.033 – ident: ref_307 doi: 10.3390/md17010019 – volume: 188 start-page: 20 year: 2013 ident: ref_265 article-title: A quantitative high throughput assay for identifying gametocytocidal compounds publication-title: Mol. Biochem. Parasitol. doi: 10.1016/j.molbiopara.2013.02.005 – volume: 374 start-page: 56 year: 2009 ident: ref_89 article-title: Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: A multicentre, randomised, phase III, non-inferiority trial publication-title: Lancet doi: 10.1016/S0140-6736(09)61117-X – ident: ref_221 doi: 10.1371/journal.pntd.0000962 – volume: 3 start-page: 61 year: 2019 ident: ref_19 article-title: Human African Trypanosomiasis: Progress and stagnation publication-title: Infect. Dis. Clin. North Am. doi: 10.1016/j.idc.2018.10.003 – volume: 91 start-page: 1385 year: 2019 ident: ref_111 article-title: Current and promising novel drug candidates against visceral leishmaniasis publication-title: Pure Appl. Chem. doi: 10.1515/pac-2018-1102 – volume: 68 start-page: 168 year: 2015 ident: ref_155 article-title: Role of cytochrome P450 2C8 in drug metabolism and interactions publication-title: Pharm. Rev. doi: 10.1124/pr.115.011411 – volume: 60 start-page: 2097 year: 2016 ident: ref_262 article-title: Luciferase-based, high-throughput assay for screening and profiling transmission-blocking compounds against Plasmodium falciparum gametocytes publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.01949-15 – volume: 2 start-page: 236 year: 2012 ident: ref_179 article-title: Recent developments in sterol 14-demethylase inhibitors for Chagas disease publication-title: Int. J. Parasitol. Drugs Drug Resist. doi: 10.1016/j.ijpddr.2011.12.002 – volume: 20 start-page: 114 year: 2015 ident: ref_200 article-title: Trypanosomatids see the light: Recent advances in bioimaging research publication-title: Drug Discov. Today doi: 10.1016/j.drudis.2014.09.012 – volume: 174 start-page: 149 year: 2017 ident: ref_101 article-title: Prevention of congenital Chagas disease by Benznidazole treatment in reproductive-age women. An observational study publication-title: Acta Trop. doi: 10.1016/j.actatropica.2017.07.004 – ident: ref_76 doi: 10.1371/journal.pntd.0002475 – volume: 340 start-page: 652 year: 1992 ident: ref_86 article-title: Efficacy and toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping sickness publication-title: Lancet doi: 10.1016/0140-6736(92)92180-N – ident: ref_48 – volume: 7 start-page: 4267 year: 2010 ident: ref_119 article-title: Antimony toxicity publication-title: Int. J. Environ. Res. Public Health doi: 10.3390/ijerph7124267 – volume: 8 start-page: 63 year: 2005 ident: ref_148 article-title: Targeting the hemozoin synthesis pathway for new antimalarial drug discovery: Technologies for in vitro β-hematin formation assay publication-title: Comb. Chem. High Throughput Screen. doi: 10.2174/1386207053328101 – volume: 11 start-page: 943 year: 2018 ident: ref_95 article-title: Clinical and pharmacological profile of benznidazole for treatment of Chagas disease publication-title: Expert Rev. Clin. Pharmacol. doi: 10.1080/17512433.2018.1509704 – volume: 20 start-page: 82 year: 2015 ident: ref_167 article-title: High-throughput screening platform for natural product-based drug discovery against 3 neglected tropical diseases: Human African trypanosomiasis, leishmaniasis, and Chagas disease publication-title: J. Biomol. Screen. doi: 10.1177/1087057114555846 – volume: 44 start-page: 873 year: 2001 ident: ref_312 article-title: Inhibition of heme detoxification processes underlies the antimalarial activity of terpene isonitrile compounds from marine sponges publication-title: J. Med. Chem. doi: 10.1021/jm0010724 – ident: ref_23 doi: 10.1371/journal.pntd.0000303 – ident: ref_25 doi: 10.1371/journal.pntd.0001691 – volume: 6 start-page: 390 year: 2001 ident: ref_78 article-title: Clinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasis publication-title: Trop. Med. Int. Health doi: 10.1046/j.1365-3156.2001.00710.x – ident: ref_258 doi: 10.1186/1471-2121-10-45 – volume: 5 start-page: 16414 year: 2015 ident: ref_268 article-title: A simple and predictive phenotypic High Content Imaging assay for Plasmodium falciparum mature gametocytes to identify malaria transmission blocking compounds publication-title: Sci. Rep. doi: 10.1038/srep16414 – volume: 24 start-page: 347 year: 2016 ident: ref_299 article-title: Marine sponges as a drug treasure publication-title: Biomol. Ther. doi: 10.4062/biomolther.2016.067 – volume: 18 start-page: 38 year: 2019 ident: ref_247 article-title: Updating the modified Thompson test by using whole-body bioluminescence imaging to replace traditional efficacy testing in experimental models of murine malaria publication-title: Malar. J. doi: 10.1186/s12936-019-2661-x – volume: 63 start-page: 260 year: 2014 ident: ref_212 article-title: In vivo imaging of trypanosomes for a better assessment of host–parasite relationships and drug efficacy publication-title: Parasitol. Int. doi: 10.1016/j.parint.2013.07.011 – volume: 18 start-page: 7475 year: 2010 ident: ref_326 article-title: 2-Hexadecynoic acid inhibits plasmodial FAS-II enzymes and arrests erythrocytic and liver stage Plasmodium infections publication-title: Bioorg. Med. Chem. doi: 10.1016/j.bmc.2010.08.055 – volume: 34 start-page: 735 year: 2018 ident: ref_263 article-title: Antimalarial transmission-blocking interventions: Past, present, and future publication-title: Trends Parasitol. doi: 10.1016/j.pt.2018.07.001 – volume: 55 start-page: 5602 year: 2011 ident: ref_108 article-title: Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.00246-11 – volume: 23 start-page: 3325 year: 2017 ident: ref_176 article-title: Parasite polyamines as pharmaceutical targets publication-title: Curr. Pharm. Des. doi: 10.2174/1381612823666170601101644 – volume: 31 start-page: e00048-18 year: 2018 ident: ref_110 article-title: Recent development of visceral leishmaniasis treatments: Successes, pitfalls, and perspectives publication-title: Clin. Microbiol. Rev. doi: 10.1128/CMR.00048-18 – volume: 10 start-page: 2387 year: 2016 ident: ref_156 article-title: Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: The evidence to date publication-title: Drug Des. Dev. Ther. doi: 10.2147/DDDT.S61443 – volume: 59 start-page: 3298 year: 2015 ident: ref_274 article-title: Imaging-based high-throughput screening assay to identify new molecules with transmission-blocking potential against Plasmodium falciparum female gamete formation publication-title: Antimicrob. Agents Chemother doi: 10.1128/AAC.04684-14 – volume: 13 start-page: 540 year: 2015 ident: ref_34 article-title: Chagas disease and transfusion medicine: A perspective from non-endemic countries publication-title: Blood Transfus. – volume: 50 start-page: 1586 year: 2006 ident: ref_281 article-title: New approach for high-throughput screening of drug activity on Plasmodium liver stages publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.50.4.1586-1589.2006 – volume: 394 start-page: 1056 year: 2019 ident: ref_49 article-title: Malaria eradication within a generation: Ambitious, achievable, and necessary publication-title: Lancet doi: 10.1016/S0140-6736(19)31139-0 – volume: 15 start-page: 217 year: 2017 ident: ref_225 article-title: Anti-trypanosomatid drug discovery: An ongoing challenge and a continuing need publication-title: Nat. Rev. Microbiol. doi: 10.1038/nrmicro.2016.193 – volume: 23 start-page: 290 year: 2017 ident: ref_30 article-title: Challenges in the management of Chagas disease in Latin-American migrants in Europe publication-title: Clin. Microbiol. Infect. doi: 10.1016/j.cmi.2017.04.013 – volume: 53 start-page: 385 year: 2007 ident: ref_152 article-title: Antimalarial drug toxicity: A review publication-title: Chemotherapy doi: 10.1159/000109767 – volume: 145 start-page: 481 year: 2018 ident: ref_130 article-title: Chemotherapeutics of visceral leishmaniasis: Present and future developments publication-title: Parasitology doi: 10.1017/S0031182017002116 – volume: 7 start-page: 89 year: 2014 ident: ref_213 article-title: In vivo imaging of mice infected with bioluminescent Trypanosoma cruzi unveils novel sites of infection publication-title: Parasit. Vectors doi: 10.1186/1756-3305-7-89 – volume: 68 start-page: 2048 year: 2013 ident: ref_264 article-title: A Plasmodium falciparum screening assay for anti-gametocyte drugs based on parasite lactate dehydrogenase detection publication-title: J. Antimicrob. Chemother. doi: 10.1093/jac/dkt165 – ident: ref_216 doi: 10.1371/journal.pone.0067441 – volume: 24 start-page: 4151 year: 2014 ident: ref_327 article-title: 2-Octadecynoic acid as a dual life stage inhibitor of Plasmodium infections and plasmodial FAS-II enzymes publication-title: Bioorg. Med. Chem. Lett. doi: 10.1016/j.bmcl.2014.07.050 – volume: 195 start-page: 927 year: 2007 ident: ref_157 article-title: Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites publication-title: J. Infect. Dis. doi: 10.1086/512241 – volume: 2 start-page: 553 year: 2002 ident: ref_81 article-title: Polyamine metabolism as chemotherapeutic target in protozoan parasites publication-title: Mini Rev. Med. Chem. doi: 10.2174/1389557023405549 – volume: 385 start-page: S80 year: 2015 ident: ref_117 article-title: Arsenic, antimony, and Leishmania: Has arsenic contamination of drinking water in India led to treatment- resistant kala-azar? publication-title: Lancet doi: 10.1016/S0140-6736(15)60395-6 – volume: 8 start-page: 754 year: 2017 ident: ref_241 article-title: Development in assay methods for in vitro antimalarial drug efficacy testing: A systematic review publication-title: Front. Pharmacol. doi: 10.3389/fphar.2017.00754 – volume: 77 start-page: C157 year: 2016 ident: ref_57 article-title: African sleeping sickness publication-title: Br. J. Hosp. Med. doi: 10.12968/hmed.2016.77.10.C157 – ident: ref_143 – ident: ref_206 doi: 10.1371/journal.pntd.0003666 – volume: 17 start-page: 45 year: 2012 ident: ref_31 article-title: Chronic Chagas’ heart disease: A disease on its way to becoming a worldwide health problem: Epidemiology, etiopathology, treatment, pathogenesis and laboratory medicine publication-title: Heart Fail. Rev. doi: 10.1007/s10741-010-9211-5 – volume: 109 start-page: 107 year: 2015 ident: ref_280 article-title: Killing the hypnozoite—Drug discovery approaches to prevent relapse in Plasmodium vivax publication-title: Pathog. Glob. Health doi: 10.1179/2047773215Y.0000000013 – ident: ref_289 doi: 10.1371/journal.pntd.0001787 – volume: 2 start-page: 281 year: 2016 ident: ref_245 article-title: High-throughput luciferase-based assay for the discovery of therapeutics that prevent malaria publication-title: ACS Infect. Dis. doi: 10.1021/acsinfecdis.5b00143 – volume: 280 start-page: 21847 year: 2005 ident: ref_237 article-title: High-throughput screening for potent and selective inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase publication-title: J. Biol. Chem. doi: 10.1074/jbc.M501100200 – volume: 108 start-page: 6404 year: 1986 ident: ref_301 article-title: Manzamine A, a novel antitumor alkaloid from a sponge publication-title: J. Am. Chem. Soc. doi: 10.1021/ja00280a055 – volume: 136 start-page: 249 year: 2004 ident: ref_196 article-title: RNA interference of Trypanosoma brucei topoisomerase IB: Both subunits are essential publication-title: Mol. Biochem. Parasitol. doi: 10.1016/j.molbiopara.2004.04.006 – volume: 191 start-page: 1922 year: 2005 ident: ref_71 article-title: Effectiveness of a 10-day melarsoprol schedule for the treatment of late-stage human African trypanosomiasis: Confirmation from a multinational study (IMPAMEL II) publication-title: J. Infect. Dis. doi: 10.1086/429929 – volume: 44 start-page: 1645 year: 2000 ident: ref_302 article-title: In vivo antimalarial activity of the beta-carboline alkaloid manzamine A publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.44.6.1645-1649.2000 – volume: 30 start-page: 481 year: 2007 ident: ref_163 article-title: Safety and toxicity of sulfadoxine/pyrimethamine: Implications for malaria prevention in pregnancy using intermittent preventive treatment publication-title: Drug Saf. doi: 10.2165/00002018-200730060-00003 – volume: 33 start-page: 119 year: 2019 ident: ref_27 article-title: American Trypanosomiasis (Chagas Disease) publication-title: Infect. Dis. Clin. North Am. doi: 10.1016/j.idc.2018.10.015 – volume: 156 start-page: 1 year: 2016 ident: ref_103 article-title: Current drug therapy and pharmaceutical challenges for Chagas disease publication-title: Acta Tropica doi: 10.1016/j.actatropica.2015.12.017 – ident: ref_70 – volume: 35 start-page: 360 year: 2011 ident: ref_201 article-title: Noninvasive biophotonic imaging for studies of infectious disease publication-title: FEMS Microbiol. Rev. doi: 10.1111/j.1574-6976.2010.00252.x – volume: 19 start-page: 7869 year: 2014 ident: ref_329 article-title: Secondary metabolites from Vietnamese marine invertebrates with activity against Trypanosoma brucei and T. cruzi publication-title: Molecules doi: 10.3390/molecules19067869 – volume: 391 start-page: 144 year: 2018 ident: ref_92 article-title: Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: A pivotal multicentre, randomised, non-inferiority trial publication-title: Lancet doi: 10.1016/S0140-6736(17)32758-7 – ident: ref_293 doi: 10.3390/md14090163 – volume: 390 start-page: 2397 year: 2017 ident: ref_17 article-title: Human African trypanosomiasis publication-title: Lancet doi: 10.1016/S0140-6736(17)31510-6 – volume: 10 start-page: 1821 year: 2015 ident: ref_186 article-title: Development of small-molecule Trypanosoma brucei N-myristoyltransferase inhibitors: Discovery and optimisation of a novel binding mode publication-title: ChemMedChem doi: 10.1002/cmdc.201500301 – volume: 17 start-page: 110 year: 2018 ident: ref_161 article-title: Efficacy and safety of artemisinin-based combination therapy for uncomplicated Plasmodium falciparum malaria in Sudan: A systematic review and meta-analysis publication-title: Malar. J. doi: 10.1186/s12936-018-2265-x – volume: 30 start-page: 65 year: 2014 ident: ref_118 article-title: Post kala-azar dermal leishmaniasis: An unresolved mystery publication-title: Trends Parasitol. doi: 10.1016/j.pt.2013.12.004 – volume: 14 start-page: 751 year: 2015 ident: ref_224 article-title: Hit and lead criteria in drug discovery for infectious diseases of the developing world publication-title: Nat. Rev. Drug Discov. doi: 10.1038/nrd4683 – volume: 274 start-page: 19383 year: 1999 ident: ref_141 article-title: Artemisinin, an endoperoxide antimalarial, disrupts the hemoglobin catabolism and heme detoxification systems in malarial parasite publication-title: J. Biol. Chem. doi: 10.1074/jbc.274.27.19383 – volume: 61 start-page: 10053 year: 2018 ident: ref_235 article-title: Target validation and identification of novel boronate inhibitors of the Plasmodium falciparum proteasome publication-title: J. Med. Chem. doi: 10.1021/acs.jmedchem.8b01161 – volume: 3 start-page: 87 year: 2003 ident: ref_43 article-title: Post-kala-azar dermal leishmaniasis publication-title: Lancet Infect. Dis. doi: 10.1016/S1473-3099(03)00517-6 – volume: 11 start-page: 599 year: 2013 ident: ref_291 article-title: Eleganolone, a diterpene from the French marine alga Bifurcaria bifurcata inhibits growth of the human pathogens Trypanosoma brucei and Plasmodium falciparum publication-title: Mar. Drugs doi: 10.3390/md11030599 – volume: 89 start-page: 961 year: 1992 ident: ref_317 article-title: Antimalarial properties of n-3 and n-6 polyunsaturated fatty acids: In vitro effects on Plasmodium falciparum and in vivo effects on P. berghei publication-title: J. Clin. Invest. doi: 10.1172/JCI115678 – volume: 174 start-page: 1 year: 2017 ident: ref_292 article-title: Antileishmanial activity of meroditerpenoids from the macroalgae Cystoseira baccata publication-title: Exp. Parasitol. doi: 10.1016/j.exppara.2017.01.002 – volume: 20 start-page: 22 year: 2015 ident: ref_198 article-title: Chagas disease drug discovery: Toward a new era publication-title: J. Biomol. Screen. doi: 10.1177/1087057114550585 – volume: 11 start-page: 596 year: 2013 ident: ref_278 article-title: Techniques & applications: A new tool for liver-stage malaria publication-title: Nat. Rev. Microbiol. doi: 10.1038/nrmicro3097 – volume: 55 start-page: 140 year: 2012 ident: ref_185 article-title: Discovery of a novel class of orally active trypanocidal N-myristoyltransferase inhibitors publication-title: J. Med. Chem. doi: 10.1021/jm201091t – volume: 14 start-page: 410 year: 2010 ident: ref_160 article-title: Clinical aspects of hemolysis in patients with Plasmodium vivax malaria treated with primaquine, in the Brazilian Amazon publication-title: Braz. J. Infect. Dis. doi: 10.1016/S1413-8670(10)70084-2 – volume: 60 start-page: 6828 year: 2016 ident: ref_60 article-title: Antileishmanial mechanism of diamidines involves targeting kinetoplasts publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.01129-16 – volume: 8 start-page: CD007483 year: 2009 ident: ref_145 article-title: Artemisinin-based combination therapy for treating uncomplicated malaria publication-title: Cochrane Database Syst. Rev. – volume: 66 start-page: 618 year: 2011 ident: ref_298 article-title: Fucoidan cures infection with both antimony-susceptible and -resistant strains of Leishmania donovani through Th1 response and macrophage-derived oxidants publication-title: J. Antimicrob. Chemother. doi: 10.1093/jac/dkq502 – volume: 18 start-page: 273 year: 2019 ident: ref_328 article-title: Marine pharmacology in 2014–2015: Marine compounds with antibacterial, antidiabetic, antifungal, anti-inflammatory, antiprotozoal, antituberculosis, antiviral, and anthelmintic activities; affecting the immune and nervous systems, and other miscellaneous mechanisms of action publication-title: Mar. Drugs doi: 10.3390/md18010005 – volume: 96 start-page: 3 year: 2002 ident: ref_39 article-title: Mechanisms of pathogenesis: Differences amongst Leishmania species publication-title: Trans. R. Soc. Trop. Med. Hyg. doi: 10.1016/S0035-9203(02)90044-1 – volume: 391 start-page: 82 year: 2018 ident: ref_26 article-title: Chagas disease publication-title: Lancet doi: 10.1016/S0140-6736(17)31612-4 – volume: 19 start-page: 1781 year: 2014 ident: ref_305 article-title: Manzamine alkaloids: Isolation, cytotoxicity, antimalarial activity and SAR studies publication-title: Drug Discov. Today doi: 10.1016/j.drudis.2014.06.010 – volume: 227 start-page: 98 year: 2016 ident: ref_52 article-title: Current status on prevention and treatment of canine leishmaniasis publication-title: Vet. Parasitol. doi: 10.1016/j.vetpar.2016.07.011 – volume: 24 start-page: 38 year: 2019 ident: ref_266 article-title: Identification of antimalarial inhibitors using late-stage gametocytes in a phenotypic live/dead assay publication-title: SLAS Discov. doi: 10.1177/2472555218796410 – volume: 45 start-page: 430 year: 1993 ident: ref_153 article-title: Mefloquine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy publication-title: Drugs doi: 10.2165/00003495-199345030-00009 – volume: 13 start-page: 717 year: 2014 ident: ref_227 article-title: Trial watch: Next-generation antimalarial from phenotypic screen shows clinical promise publication-title: Nat. Rev. Drug Discov. doi: 10.1038/nrd4457 – volume: 67 start-page: 2576 year: 2012 ident: ref_129 article-title: Miltefosine: A review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis publication-title: J. Antimicrob. Chemother. doi: 10.1093/jac/dks275 – ident: ref_259 doi: 10.1186/1471-2334-12-1 – volume: 13 start-page: 427 year: 2012 ident: ref_173 article-title: Adaptation of High-Throughput Screening in drug discovery—Toxicological screening tests publication-title: Int. J. Mol. Sci. – volume: 8 start-page: 47 year: 2010 ident: ref_314 article-title: Inhibitory activity of marine sponge-derived natural products against parasitic protozoa publication-title: Mar. Drugs doi: 10.3390/md8010047 – volume: 54 start-page: 3597 year: 2010 ident: ref_257 article-title: Discovery of potent small-molecule inhibitors of multidrug-resistant Plasmodium falciparum using a novel miniaturized high-throughput luciferase-based assay publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.00431-10 – volume: 64 start-page: 370 year: 2009 ident: ref_218 article-title: Transgenic Leishmania donovani clinical isolates expressing green fluorescent protein constitutively for rapid and reliable ex vivo drug screening publication-title: J. Antimicrob. Chemother. doi: 10.1093/jac/dkp206 – volume: 164 start-page: 113 year: 2011 ident: ref_320 article-title: First total synthesis and antileishmanial activity of (Z)-16-methyl-11-heptadecenoic acid, a new marine fatty acid from the sponge Dragmaxia undata publication-title: Chem. Phys. Lipids doi: 10.1016/j.chemphyslip.2010.11.006 – volume: 36 start-page: 32 year: 2016 ident: ref_164 article-title: Strategies for the optimization of natural leads to anticancer drugs or drug candidates publication-title: Med. Res. Rev. doi: 10.1002/med.21377 – volume: 2 start-page: 1003 year: 2003 ident: ref_75 article-title: Mechanisms of arsenical and diamidine uptake and resistance in Trypanosoma brucei publication-title: Eukaryot. Cell doi: 10.1128/EC.2.5.1003-1008.2003 – volume: 59 start-page: 2530 year: 2016 ident: ref_109 article-title: Repositioning antitubercular 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for Neglected Tropical Diseases: Structure-activity studies on a preclinical candidate for visceral leishmaniasis publication-title: J. Med. Chem. doi: 10.1021/acs.jmedchem.5b01699 – volume: 73 start-page: 1404 year: 2010 ident: ref_315 article-title: Antiprotozoal steroidal saponins from the marine sponge Pandaros acanthifolium publication-title: J. Nat. Prod. doi: 10.1021/np100348x – volume: 19 start-page: 156 year: 2013 ident: ref_240 article-title: Malaria biology and disease pathogenesis: Insights for new treatments publication-title: Nat. Med. doi: 10.1038/nm.3073 – volume: 35 start-page: 1022 year: 2003 ident: ref_210 article-title: Comparison of noninvasive fluorescent and bioluminescent small animal optical imaging publication-title: Biotechniques doi: 10.2144/03355rr02 – volume: 19 start-page: 264 year: 1990 ident: ref_151 article-title: Clinical pharmacokinetics of mefloquine publication-title: Clin. Pharmacokinet. doi: 10.2165/00003088-199019040-00002 – volume: 25 start-page: 432 year: 2009 ident: ref_204 article-title: Reporter genes facilitating discovery of drugs targeting protozoan parasites publication-title: Trends Parasitol. doi: 10.1016/j.pt.2009.06.006 – volume: 27 start-page: 173 year: 2017 ident: ref_124 article-title: The care and feeding of a commercial liposomal product: Liposomal amphotericin B (AmBisome®) publication-title: J. Liposome Res. doi: 10.1080/08982104.2017.1380664 – volume: 47 start-page: 3512 year: 2004 ident: ref_303 article-title: New manzamine alkaloids from an Indo-Pacific sponge. Pharmacokinetics, oral availability, and the significant activity of several manzamines against HIV-I, AIDS opportunistic infections, and inflammatory diseases publication-title: J. Med. Chem. doi: 10.1021/jm030475b – volume: 210 start-page: 332 year: 1980 ident: ref_80 article-title: Polyamine metabolism: A potential therapeutic target in trypanosomes publication-title: Science doi: 10.1126/science.6775372 – volume: 152 start-page: 1155 year: 2007 ident: ref_64 article-title: Human African trypanosomiasis: Pharmacological re-engagement with a neglected disease publication-title: Br. J. Pharmacol. doi: 10.1038/sj.bjp.0707354 – volume: 276 start-page: 3971 year: 2001 ident: ref_115 article-title: Novel Intracellular SbV reducing activity correlates with antimony susceptibility in Leishmania donovani publication-title: J. Biol. Chem. doi: 10.1074/jbc.M005423200 – volume: 57 start-page: 2119 year: 2017 ident: ref_172 article-title: Cheminformatic analysis of antimalarial chemical space illuminates therapeutic mechanisms and offers strategies for therapy development publication-title: J. Chem. Inf. Model. doi: 10.1021/acs.jcim.7b00072 – ident: ref_290 doi: 10.3390/md17030192 – volume: 12 start-page: 7 year: 2019 ident: ref_94 article-title: Current trends in the pharmacological management of Chagas disease publication-title: Int. J. Parasitol. Drugs Drug. Resist. doi: 10.1016/j.ijpddr.2019.11.004 – volume: 12 start-page: 881 year: 2013 ident: ref_120 article-title: Toxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin B publication-title: Expert Opin. Drug Saf. doi: 10.1517/14740338.2013.827168 – ident: ref_83 doi: 10.3390/medsci6010012 – ident: ref_21 – volume: 362 start-page: 504 year: 2010 ident: ref_123 article-title: Single-dose liposomal amphotericin B for visceral leishmaniasis in India publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa0903627 – volume: 373 start-page: 456 year: 2015 ident: ref_28 article-title: Chagas’ Disease publication-title: N. Engl. J. Med. doi: 10.1056/NEJMra1410150 – volume: 78 start-page: 861 year: 2018 ident: ref_150 article-title: Drugs in development for malaria publication-title: Drugs doi: 10.1007/s40265-018-0911-9 – volume: 116 start-page: 1955 year: 2017 ident: ref_253 article-title: Adaptation and optimization of a fluorescence-based assay for in vivo antimalarial drug screening publication-title: Parasitol. Res. doi: 10.1007/s00436-017-5477-z – volume: 7 start-page: 407 year: 2014 ident: ref_149 article-title: Shifting from quinine to artesunate as first-line treatment of severe malaria in children and adults: Saving more lives publication-title: J. Infect. Public Health doi: 10.1016/j.jiph.2014.04.007 – volume: 10 start-page: 263 year: 2011 ident: ref_140 article-title: Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration publication-title: Malar. J. doi: 10.1186/1475-2875-10-263 – volume: 56 start-page: 7719 year: 2013 ident: ref_169 article-title: Drug discovery for neglected diseases: Molecular target-based and phenotypic approaches publication-title: J. Med. Chem. doi: 10.1021/jm400362b – volume: 122 start-page: 217 year: 2002 ident: ref_68 article-title: Evidence for a non-LDL-mediated entry route for the trypanocidal drug suramin in Trypanosoma brucei publication-title: Mol. Biochem. Parasitol. doi: 10.1016/S0166-6851(02)00096-8 – volume: 58 start-page: 78 year: 2014 ident: ref_222 article-title: Development of an ex vivo lymph node explant model for identification of novel molecules active against Leishmania major publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.00887-13 – volume: 10 start-page: 61 year: 2012 ident: ref_256 article-title: Validating a firefly luciferase-based high-throughput screening assay for antimalarial drug discovery publication-title: Assay Drug Dev. Technol. doi: 10.1089/adt.2011.0378 – volume: 68 start-page: 1530 year: 2019 ident: ref_131 article-title: Pharmacokinetics, safety, and efficacy of an allometric miltefosine regimen for the treatment of visceral leishmaniasis in eastern African children: An open-label, phase ii clinical trial publication-title: Clin. Infect. Dis. – volume: 11 start-page: 2072 year: 2011 ident: ref_97 article-title: Trypanocidal activity of nitroaromatic prodrugs: Current treatments and future perspectives publication-title: Curr. Top. Med. Chem. doi: 10.2174/156802611796575894 – volume: 42 start-page: 671 year: 1992 ident: ref_106 article-title: The pharmacokinetics of nifurtimox in chronic renal failure publication-title: Eur. J. Clin. Pharmacol. – volume: 4 start-page: 355 year: 2014 ident: ref_168 article-title: Target-based vs. phenotypic screenings in Leishmania drug discovery: A marriage of convenience or a dialogue of the deaf? publication-title: Int. J. Parasitol. Drugs Drug Resist. doi: 10.1016/j.ijpddr.2014.05.001 – volume: 14 start-page: 104 year: 2013 ident: ref_282 article-title: A microscale human liver platform that supports the hepatic stages of Plasmodium falciparum and vivax publication-title: Cell Host Microbe doi: 10.1016/j.chom.2013.06.005 – volume: 74 start-page: 529 year: 2009 ident: ref_191 article-title: Dissecting the essentiality of the bifunctional trypanothione synthetase-amidase in Trypanosoma brucei using chemical and genetic methods publication-title: Mol. Microbiol. doi: 10.1111/j.1365-2958.2009.06761.x – volume: 24 start-page: 346 year: 2019 ident: ref_189 article-title: Accelerating drug discovery efforts for trypanosomatidic infections using an integrated transnational academic drug discovery platform publication-title: SLAS Discov. doi: 10.1177/2472555218823171 – volume: 9 start-page: 2131 year: 2011 ident: ref_308 article-title: Kinase Inhibitors from marine sponges publication-title: Mar. Drugs doi: 10.3390/md9102131 – volume: 53 start-page: 2557 year: 2009 ident: ref_251 article-title: Assessment of malaria in vitro drug combination screening and mixed-strain infections using the malaria SYBR green I-based fluorescence assay publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.01370-08 – volume: 103 start-page: 1445 year: 2008 ident: ref_331 article-title: Antiprotozoan activity of Brazilian marine cnidarian extracts and of a modified steroid from the octocoral Carijoa riisei publication-title: Parasitol. Res. doi: 10.1007/s00436-008-1154-6 – volume: 14 start-page: 53 year: 2012 ident: ref_116 article-title: Leishmaniasis: An update of current pharmacotherapy publication-title: Expert Opin. Pharmacother. doi: 10.1517/14656566.2013.755515 – volume: 351 start-page: 1700373 year: 2018 ident: ref_192 article-title: Molecular insights into trypanothione reductase-inhibitor interaction: A structure-based review publication-title: Archiv. Pharm. doi: 10.1002/ardp.201700373 – volume: 188 start-page: 63 year: 2013 ident: ref_162 article-title: Folate metabolism in human malaria parasites—75 years on publication-title: Mol. Biochem. Parasitol. doi: 10.1016/j.molbiopara.2013.02.008 – volume: 8 start-page: 295 year: 2018 ident: ref_232 article-title: Functional screening of selective mitochondrial inhibitors of Plasmodium publication-title: Int. J. Parasitol. Drugs Drug Resist. doi: 10.1016/j.ijpddr.2018.04.007 – volume: 8 start-page: 2733 year: 2010 ident: ref_296 article-title: Effect of elatol, isolated from red seaweed Laurencia dendroidea, on Leishmania amazonensis publication-title: Mar. Drugs. doi: 10.3390/md8112733 – volume: 30 start-page: 289 year: 2014 ident: ref_96 article-title: Nitro drugs for the treatment of trypanosomatid diseases: Past, present, and future prospects publication-title: Trends Parasitol. doi: 10.1016/j.pt.2014.04.003 – volume: 281 start-page: 14529 year: 2006 ident: ref_85 article-title: Regulation of ornithine decarboxylase publication-title: J. Biol. Chem. doi: 10.1074/jbc.R500031200 – volume: 24 start-page: 265 year: 2014 ident: ref_286 article-title: New drugs with antiprotozoal activity from marine algae: A review publication-title: Rev. Bras. Farmacol. doi: 10.1016/j.bjp.2014.07.001 – ident: ref_136 doi: 10.1371/journal.pntd.0005635 – volume: 92 start-page: 103276 year: 2019 ident: ref_295 article-title: Antiprotozoal activities of marine polyether triterpenoids publication-title: Bioorg. Chem. doi: 10.1016/j.bioorg.2019.103276 – volume: 13 start-page: 2418 year: 2013 ident: ref_35 article-title: Donor-derived Trypanosoma cruzi infection in solid organ recipients in the United States, 2001–2011 publication-title: Am. J. Transplant. doi: 10.1111/ajt.12340 – volume: 51 start-page: 6153 year: 2010 ident: ref_321 article-title: The first total synthesis of the (±)-17-methyl-trans-4,5-methyleneoctadecanoic acid and related analogs with antileishmanial activity publication-title: Tetrahedron Lett. doi: 10.1016/j.tetlet.2010.09.083 – volume: 56 start-page: 5264 year: 2012 ident: ref_197 article-title: Indotecan (LMP400) and AM13-55: Two novel indenoisoquinolines show potential for treating visceral leishmaniasis publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.00499-12 – volume: 105 start-page: 5022 year: 2008 ident: ref_105 article-title: A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.0711014105 – volume: 77 start-page: 733 year: 2011 ident: ref_297 article-title: Antileishmanial sesquiterpenes from the Brazilian red alga Laurencia dendroidea publication-title: Planta Med. doi: 10.1055/s-0030-1250526 – volume: 51 start-page: 245 year: 2016 ident: ref_324 article-title: Novel very long-chain α-methoxylated α5,9 fatty acids from the sponge Asteropus niger are effective inhibitors of topoisomerases IB publication-title: Lipids doi: 10.1007/s11745-015-4114-9 – volume: 203 start-page: 1445 year: 2011 ident: ref_272 article-title: A high-throughput screen targeting malaria transmission stages opens new avenues for drug development publication-title: J. Infect. Dis. doi: 10.1093/infdis/jir037 – volume: 21 start-page: 56 year: 1988 ident: ref_67 article-title: Spread of Trypanosoma brucei to the nervous system: Early attack on circumventricular organs and sensory ganglia publication-title: J. Neurosci. Res. doi: 10.1002/jnr.490210109 – ident: ref_133 doi: 10.1371/journal.pntd.0004118 – volume: 26 start-page: 22 year: 1986 ident: ref_66 article-title: Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection publication-title: J. Clin. Pharmacol. doi: 10.1002/j.1552-4604.1986.tb02897.x – volume: 114 start-page: 11138 year: 2014 ident: ref_56 article-title: Recent approaches to chemical discovery and development against malaria and the neglected tropical diseases human African trypanosomiasis and schistosomiasis publication-title: Chem. Rev. doi: 10.1021/cr500098f – volume: 32 start-page: 1655 year: 2002 ident: ref_142 article-title: Artemisinin: Mechanisms of action, resistance and toxicity publication-title: Int. J. Parasitol. doi: 10.1016/S0020-7519(02)00194-7 – volume: 1601 start-page: 97 year: 2017 ident: ref_248 article-title: SYBR® Green I-based fluorescence assay to assess cell viability of malaria parasites for routine use in compound screening publication-title: Methods Mol. Biol. doi: 10.1007/978-1-4939-6960-9_9 – volume: 25 start-page: 471 year: 2006 ident: ref_107 article-title: Toxic side effects of drugs used to treat CD (American trypanosomiasis) publication-title: Hum. Exp. Toxicol. doi: 10.1191/0960327106het653oa – volume: 2 start-page: 11 year: 2012 ident: ref_199 article-title: Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it? publication-title: Int. J. Parasitol. Drugs Drug Resist. doi: 10.1016/j.ijpddr.2012.01.003 – volume: 356 start-page: 2571 year: 2007 ident: ref_134 article-title: Injectable paromomycin for Visceral leishmaniasis in India publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa066536 – volume: 172 start-page: 58 year: 2013 ident: ref_323 article-title: Recent developments in the antiprotozoal and anticancer activities of the 2-alkynoic fatty acids publication-title: Chem. Phys. Lipids doi: 10.1016/j.chemphyslip.2013.05.002 – volume: 57 start-page: 390 year: 2013 ident: ref_102 article-title: Benznidazole-related adverse drug reactions and their relationship to serum drug concentrations in patients with chronic Chagas disease. Antimicrob publication-title: Agents Chemother. doi: 10.1128/AAC.01401-12 – volume: 152 start-page: 1 year: 2007 ident: ref_61 article-title: S-Adenosyl-methionine in protozoan parasites: Functions, synthesis and regulation publication-title: Mol. Biochem. Parasitol. doi: 10.1016/j.molbiopara.2006.11.013 – volume: 120 start-page: 80 year: 2008 ident: ref_246 article-title: Plasmodium falciparum: Development of a transgenic line for screening antimalarials using firefly luciferase as the reporter publication-title: Exp. Parasitol. doi: 10.1016/j.exppara.2008.05.003 – volume: 84 start-page: 323 year: 2009 ident: ref_146 article-title: Pharmacokinetic and toxicological profile of artemisinin compounds: An update publication-title: Pharmacology doi: 10.1159/000252658 – volume: 69 start-page: 520 year: 2008 ident: ref_188 article-title: Chemical and genetic validation of dihydrofolate reductase-thymidylate synthase as a drug target in African trypanosomes publication-title: Mol. Microbiol. doi: 10.1111/j.1365-2958.2008.06305.x – volume: 73 start-page: 897 year: 2015 ident: ref_41 article-title: Cutaneous and mucocutaneous leishmaniasis: Clinical perspectives publication-title: J. Am. Acad. Dermatol. doi: 10.1016/j.jaad.2014.08.051 – volume: 142 start-page: 235 year: 2014 ident: ref_32 article-title: Chagasic megacolon: Enteric neurons and related structures publication-title: Histochem. Cell. Biol. doi: 10.1007/s00418-014-1250-x – volume: 48 start-page: e29 year: 2018 ident: ref_33 article-title: Chagas disease in Europe: A long way to go publication-title: Eur. J. Intern. Med. doi: 10.1016/j.ejim.2017.09.022 – volume: 71 start-page: 1218 year: 2008 ident: ref_304 article-title: Kinetic studies and bioactivity of potential manzamine prodrugs publication-title: J. Nat. Prod. doi: 10.1021/np800163u – volume: 22 start-page: 1516 year: 2017 ident: ref_174 article-title: Leishmaniasis drug discovery: Recent progress and challenges in assay development publication-title: Drug Discov.Today doi: 10.1016/j.drudis.2017.06.004 – volume: 20 start-page: 1797 year: 2019 ident: ref_98 article-title: An evaluation of benznidazole as a Chagas disease therapeutic publication-title: Expert Opin. Pharmacother. doi: 10.1080/14656566.2019.1650915 – volume: 6 start-page: 215 year: 1987 ident: ref_69 article-title: Common elements on the surface of glycolytic enzymes from Trypanosoma brucei may serve as topogenic signals for import into glycosomes publication-title: EMBO J. doi: 10.1002/j.1460-2075.1987.tb04741.x – volume: 4 start-page: 2337 year: 2012 ident: ref_273 article-title: Whole-cell in vitro screening for gametocytocidal compounds publication-title: Future Med. Chem. doi: 10.4155/fmc.12.188 – ident: ref_45 – ident: ref_283 doi: 10.1371/journal.pone.0014275 – volume: 49 start-page: 3776 year: 2005 ident: ref_211 article-title: Use of Leishmania donovani field isolates expressing the luciferase reporter gene in in vitro drug screening publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.49.9.3776-3783.2005 – volume: 8 start-page: 294 year: 2009 ident: ref_252 article-title: A comparative study of a flow-cytometry-based assessment of in vitro Plasmodium falciparum drug sensitivity publication-title: Malar. J. doi: 10.1186/1475-2875-8-294 – volume: 392 start-page: 951 year: 2018 ident: ref_38 article-title: Leishmaniasis publication-title: Lancet doi: 10.1016/S0140-6736(18)31204-2 – volume: 56 start-page: 5982 year: 2012 ident: ref_242 article-title: In vitro activity of fluorescent dyes against asexual blood stages of Plasmodium falciparum publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.00709-12 – volume: 145 start-page: 453 year: 2018 ident: ref_47 article-title: Evaluating drug resistance in visceral leishmaniasis: The challenges publication-title: Parasitology doi: 10.1017/S0031182016002031 – volume: 3 start-page: 733 year: 2007 ident: ref_132 article-title: Miltefosine in the treatment of leishmaniasis: Clinical evidence for informed clinical risk management publication-title: Ther. Clin. Risk Manag. – volume: 10 start-page: 775 year: 2015 ident: ref_231 article-title: Yeast-based high-throughput screen identifies Plasmodium falciparum equilibrative nucleoside transporter 1 inhibitors that kill malaria parasites publication-title: ACS Chem. Biol. doi: 10.1021/cb500981y – volume: 70 start-page: 491 year: 1972 ident: ref_316 article-title: Effect of long-chain fatty acids on some trypanosomatid flagellates publication-title: J. Gen. Microbiol. doi: 10.1099/00221287-70-3-491 – volume: 48 start-page: 3010 year: 2004 ident: ref_127 article-title: Possible mechanism of miltefosine-mediated death of Leishmania donovani publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.48.8.3010-3015.2004 – volume: 97 start-page: 928 year: 2015 ident: ref_306 article-title: Manzamine alkaloids as antileishmanial agents: A review publication-title: Eur. J. Med. Chem. doi: 10.1016/j.ejmech.2014.07.006 – volume: 15 start-page: 1481 year: 2016 ident: ref_53 article-title: The RTS,S/AS01 malaria vaccine in children 5 to 17 months of age at first vaccination publication-title: Expert Rev. Vaccin. doi: 10.1080/14760584.2016.1236689 – volume: 370 start-page: 1899 year: 2014 ident: ref_180 article-title: Randomized trial of posaconazole and benznidazole for chronic Chagas’ disease publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1313122 – volume: 7 start-page: 130 year: 2009 ident: ref_310 article-title: Marine antimalarials publication-title: Mar. Drugs doi: 10.3390/md7020130 – volume: 110 start-page: 1 year: 2016 ident: ref_159 article-title: Primaquine treatment and relapse in Plasmodium vivax malaria publication-title: Pathog. Glob. Health doi: 10.1080/20477724.2015.1133033 – volume: 102 start-page: 346 year: 2008 ident: ref_249 article-title: Performance and reliability of the SYBR Green I based assay for the routine monitoring of susceptibility of Plasmodium falciparum clinical isolates publication-title: Trans. R. Soc. Trop. Med. Hyg. doi: 10.1016/j.trstmh.2008.01.021 – volume: 9 start-page: 1837 year: 2018 ident: ref_279 article-title: A comprehensive model for assessment of liver stage therapies targeting Plasmodium vivax and Plasmodium falciparum publication-title: Nat. Commun. doi: 10.1038/s41467-018-04221-9 – volume: 1787 start-page: 41 year: 2018 ident: ref_260 article-title: Phenotypic screening of small molecules with antimalarial activity for three different parasitic life stages publication-title: Methods Mol. Biol. doi: 10.1007/978-1-4939-7847-2_3 – volume: 22 start-page: 125 year: 2017 ident: ref_203 article-title: Evaluation of parameters impacting drug susceptibility in intracellular Trypanosoma cruzi assay protocols publication-title: SLAS Discov. doi: 10.1177/1087057116673796 – volume: 114 start-page: 11131 year: 2014 ident: ref_55 article-title: Introduction: Drug discovery and development for neglected diseases publication-title: Chem. Rev. doi: 10.1021/cr500546h – volume: 6 start-page: 2214 year: 2011 ident: ref_182 article-title: Identification of inhibitors of the Leishmania cdc2-related protein kinase CRK3 publication-title: ChemMedChem doi: 10.1002/cmdc.201100344 – volume: 13 start-page: 389 year: 2015 ident: ref_219 article-title: High-content assay for measuring intracellular growth of Leishmania in human macrophages publication-title: Assay Drug Dev. Technol. doi: 10.1089/adt.2015.652 – volume: 4 start-page: 431 year: 2018 ident: ref_230 article-title: Fragment-Based Screening of a natural product library against 62 potential malaria drug targets employing native mass spectrometry publication-title: ACS Infect. Dis. doi: 10.1021/acsinfecdis.7b00197 – ident: ref_287 doi: 10.3390/md15110323 – volume: 5 start-page: 8771 year: 2015 ident: ref_205 article-title: New compound sets identified from high throughput phenotypic screening against three kinetoplastid parasites: An open resource publication-title: Sci. Rep. doi: 10.1038/srep08771 – volume: 24 start-page: 1209 year: 2019 ident: ref_220 article-title: Walking a tightrope: Drug discovery in visceral leishmaniasis publication-title: Drug Discov. Today doi: 10.1016/j.drudis.2019.03.007 – volume: 42 start-page: 1 year: 2018 ident: ref_239 article-title: The antimalarial pipeline publication-title: Curr. Opin. Pharmacol. doi: 10.1016/j.coph.2018.05.006 – volume: 51 start-page: 63 year: 2011 ident: ref_187 article-title: Folate metabolic pathways in Leishmania publication-title: Essays Biochem. doi: 10.1042/bse0510063 – volume: 362 start-page: eaat9446 year: 2018 ident: ref_284 article-title: Open-source discovery of chemical leads for next-generation chemoprotective antimalarials publication-title: Science doi: 10.1126/science.aat9446 – volume: 102 start-page: 294 year: 2020 ident: ref_29 article-title: Chagas disease infection prevalence and vector exposure in a high-risk population of Texas hunters publication-title: Am. J. Trop. Med. Hyg. doi: 10.4269/ajtmh.19-0310 – ident: ref_63 doi: 10.1002/14651858.CD006201.pub3 – ident: ref_144 doi: 10.1016/S0140-6736(03)15162-8 – volume: 16 start-page: 147 year: 2017 ident: ref_276 article-title: Novel lead structures with both Plasmodium falciparum gametocytocidal and asexual blood stage activity identified from high throughput compound screening publication-title: Malar. J. doi: 10.1186/s12936-017-1805-0 – volume: 348 start-page: 1196 year: 1996 ident: ref_154 article-title: Systematic review of amodiaquine treatment in uncomplicated malaria publication-title: Lancet doi: 10.1016/S0140-6736(96)06217-4 – volume: 75 start-page: 65 year: 2011 ident: ref_178 article-title: Targeting Trypanosoma cruzi sterol 14α-demethylase (CYP51). Chagas disease, Part, A publication-title: Adv. Parasitol. doi: 10.1016/B978-0-12-385863-4.00004-6 – volume: 19 start-page: 116 year: 2012 ident: ref_228 article-title: Global phenotypic screening for antimalarials publication-title: Chem. Biol. doi: 10.1016/j.chembiol.2012.01.004 – ident: ref_50 – volume: 32 start-page: 697 year: 2016 ident: ref_226 article-title: Phenotypic screens in antimalarial drug discovery publication-title: Trends Parasitol. doi: 10.1016/j.pt.2016.04.014 – volume: 6 start-page: 750 year: 2017 ident: ref_37 article-title: Leishmaniasis: A review publication-title: F1000Res doi: 10.12688/f1000research.11120.1 – volume: 25 start-page: 464 year: 2009 ident: ref_202 article-title: Imaging Leishmania development in their host cells publication-title: Trends Parasitol. doi: 10.1016/j.pt.2009.07.006 – volume: 107 start-page: 251 year: 2000 ident: ref_209 article-title: Targeted integration into a rRNA locus results in uniform and high-level expression of transgenes in Leishmania amastigotes publication-title: Mol. Biochem. Parasitol. doi: 10.1016/S0166-6851(00)00195-X – volume: 17 start-page: 9 year: 2018 ident: ref_243 article-title: Unclear association between levels of Plasmodium falciparum lactate dehydrogenase (PfLDH) in saliva of malaria patients and blood parasitaemia: Diagnostic implications? publication-title: Malar. J. doi: 10.1186/s12936-017-2151-y – volume: 79 start-page: 215 year: 2019 ident: ref_90 article-title: Fexinidazole: First global approval publication-title: Drugs doi: 10.1007/s40265-019-1051-6 – volume: 17 start-page: 589 year: 2016 ident: ref_7 article-title: Review on the clinical use of eribulin mesylate for the treatment of breast cancer publication-title: Expert Opin. Pharmacother. doi: 10.1517/14656566.2016.1146683 – volume: 30 start-page: 1284 year: 2013 ident: ref_165 article-title: Matching the power of high throughput screening to the chemical diversity of natural products publication-title: Nat. Prod. Rep. doi: 10.1039/c3np70052f – volume: 23 start-page: 589 year: 2007 ident: ref_175 article-title: Target assessment for antiparasitic drug discovery publication-title: Trends Parasitol. doi: 10.1016/j.pt.2007.08.019 – ident: ref_2 doi: 10.1159/isbn.978-3-318-00599-8 – ident: ref_22 – volume: 110 start-page: 195 year: 2000 ident: ref_208 article-title: Episomal and stable expression of the luciferase reporter gene for quantifying Leishmania spp. infections in macrophages and in animal models publication-title: Mol. Biochem. Parasitol. doi: 10.1016/S0166-6851(00)00270-X – volume: 77 start-page: 89 year: 2007 ident: ref_137 article-title: Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: A retrospective comparison with 30-day sodium stibogluconate monotherapy publication-title: Am. J. Trop. Med. Hyg. doi: 10.4269/ajtmh.2007.77.89 – volume: 34 start-page: 183 year: 1990 ident: ref_121 article-title: Amphotericin B: Current understanding of mechanisms of action publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.34.2.183 – volume: 63 start-page: 391 year: 2018 ident: ref_207 article-title: A new chimeric triple reporter fusion protein as a tool for in vitro and in vivo multimodal imaging to monitor the development of African trypanosomes and Leishmania parasites publication-title: Infect. Genet. Evol. doi: 10.1016/j.meegid.2018.01.011 – volume: 2018 start-page: 8676578 year: 2018 ident: ref_194 article-title: Relevance of trypanothione reductase inhibitors on Trypanosoma cruzi infection: A systematic review, meta-analysis, and in silico integrated approach publication-title: Oxid. Med. Cell. Longev. – volume: 93 start-page: 299 year: 2013 ident: ref_171 article-title: Phenotypic vs. target-based drug discovery for first-in-class medicines publication-title: Clin. Pharmacol. Ther. doi: 10.1038/clpt.2012.236 – ident: ref_300 doi: 10.1371/journal.pone.0138528 – volume: 137 start-page: 1987 year: 2010 ident: ref_65 article-title: Chemotherapy against human African trypanosomiasis: Is there a road to success? publication-title: Parasitology doi: 10.1017/S0031182010001137 – volume: 24 start-page: 561 year: 2016 ident: ref_1 article-title: Marine-derived pharmaceuticals—Challenges and opportunities publication-title: Biomol. Ther. doi: 10.4062/biomolther.2016.181 – volume: 285 start-page: 242 year: 1999 ident: ref_74 article-title: A nucleoside transporter from Trypanosoma brucei involved in drug resistance publication-title: Science doi: 10.1126/science.285.5425.242 – volume: 58 start-page: 1175 year: 2015 ident: ref_139 article-title: The discovery of artemisinin and the Nobel Prize in Physiology or Medicine publication-title: Sci. China Life Sci. doi: 10.1007/s11427-015-4948-7 – volume: 341 start-page: 1795 year: 1999 ident: ref_126 article-title: Oral miltefosine for Indian visceral leishmaniasis publication-title: N. Engl. J. Med. doi: 10.1056/NEJM199912093412403 – volume: 9 start-page: 400 year: 2011 ident: ref_311 article-title: Anti-malarial, anti-algal, anti-tubercular, anti-bacterial, anti-photosynthetic, and anti-fouling activity of diterpene and diterpene isonitriles from the tropical marine sponge Cymbastela hooperi publication-title: Org. Biomol. Chem. doi: 10.1039/C0OB00326C – volume: 8 start-page: 40 year: 2019 ident: ref_16 article-title: The 2017 Oslo conference report on neglected tropical diseases and emerging/re-emerging infectious diseases—Focus on populations underserved publication-title: Infect. Dis. Poverty doi: 10.1186/s40249-019-0550-8 – volume: 200 start-page: 105173 year: 2019 ident: ref_51 article-title: An overview of leishmanization experience: A successful control measure and a tool to evaluate candidate vaccines publication-title: Acta Trop. doi: 10.1016/j.actatropica.2019.105173 – volume: 34 start-page: 818 year: 2018 ident: ref_87 article-title: The long wait for a new drug for Human African Trypanosomiasis publication-title: Trends Parasitol. doi: 10.1016/j.pt.2018.08.006 – volume: 57 start-page: 6050 year: 2013 ident: ref_269 article-title: Identification of MMV malaria box inhibitors of Plasmodium falciparum early-stage gametocytes using a luciferase-based high-throughput assay publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.00870-13 – ident: ref_275 doi: 10.1371/journal.pone.0105817 – volume: 80 start-page: PB8 year: 2014 ident: ref_313 article-title: Characterization of membranolides B-H from Dendrilla membranosa and their activity against leishmaniasis publication-title: Planta Med. doi: 10.1055/s-0034-1382374 – volume: 66 start-page: 444 year: 2018 ident: ref_135 article-title: Long-term clinical outcomes in visceral leishmaniasis/human immunodeficiency virus-coinfected patients during and after pentamidine secondary prophylaxis in Ethiopia: A single-arm clinical trial publication-title: Clin. Infect. Dis. doi: 10.1093/cid/cix807 – ident: ref_215 doi: 10.1371/journal.pntd.0000509 – volume: 61 start-page: e01912-16 year: 2017 ident: ref_99 article-title: Pharmacokinetics of benznidazole in healthy volunteers and implications in future clinical trials publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.01912-16 – volume: 9 start-page: 2369 year: 2011 ident: ref_288 article-title: 4-Acetoxydolastane diterpene from the Brazilian brown alga Canistrocarpus cervicornis as antileishmanial agent publication-title: Mar. Drugs doi: 10.3390/md9112369 – volume: 19 start-page: 114 year: 2016 ident: ref_270 article-title: High-throughput assay and discovery of small molecules that interrupt malaria transmission publication-title: Cell Host Microbe doi: 10.1016/j.chom.2015.12.001 – volume: 16 start-page: e304 year: 2016 ident: ref_46 article-title: Elimination of visceral leishmaniasis on the Indian subcontinent publication-title: Lancet Infect. Dis. doi: 10.1016/S1473-3099(16)30140-2 – volume: 198 start-page: 105 year: 2019 ident: ref_93 article-title: Drug discovery for Chagas disease: A viewpoint publication-title: Acta Trop. doi: 10.1016/j.actatropica.2019.105107 – volume: 18 start-page: 419 year: 2018 ident: ref_181 article-title: Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: A proof-of-concept, randomised, placebo-controlled trial publication-title: Lancet Infect. Dis. doi: 10.1016/S1473-3099(17)30538-8 – volume: 97 start-page: 1289 year: 2017 ident: ref_104 article-title: Experimental and clinical treatment of Chagas disease: A review publication-title: Am. J. Trop. Med. Hyg. doi: 10.4269/ajtmh.16-0761 – volume: 122 start-page: 113 year: 2012 ident: ref_254 article-title: Flow cytometric enumeration of Plasmodium berghei-infected red blood cells stained with SYBR green I publication-title: Acta Trop. doi: 10.1016/j.actatropica.2011.12.010 – volume: 365 start-page: eaau1682 year: 2019 ident: ref_233 article-title: Validation of the protein kinase PfCLK3 as a multistage cross-species malarial drug target publication-title: Science doi: 10.1126/science.aau1682 – volume: 33 start-page: 382 year: 2016 ident: ref_3 article-title: Marine natural products publication-title: Nat. Prod. Rep. doi: 10.1039/C5NP00156K – volume: 5 start-page: 65 year: 2015 ident: ref_77 article-title: Chimerization at the AQP2-AQP3 locus is the genetic basis of melarsoprol-pentamidine cross-resistance in clinical Trypanosoma brucei gambiense isolates publication-title: Int. J. Parasitol. Drugs Drug Resist. doi: 10.1016/j.ijpddr.2015.04.002 – volume: 48 start-page: 1807 year: 2004 ident: ref_255 article-title: Novel, rapid, and inexpensive cell-based quantification of antimalarial drug efficacy publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.48.5.1807-1810.2004 – volume: 34 start-page: 178 year: 2018 ident: ref_91 article-title: Fexinidazole: A new drug for African sleeping sickness on the horizon publication-title: Trends Parasitol. doi: 10.1016/j.pt.2017.12.002 – volume: 55 start-page: 586 year: 1996 ident: ref_58 article-title: The efficacy of pentamidine in the treatment of early-late stage Trypanosoma brucei gambiense trypanosomiasis publication-title: Am. J. Trop. Med. Hyg. doi: 10.4269/ajtmh.1996.55.586 – volume: 383 start-page: 723 year: 2014 ident: ref_15 article-title: Malaria publication-title: Lancet doi: 10.1016/S0140-6736(13)60024-0 – volume: 16 start-page: P1113 year: 2016 ident: ref_14 article-title: Global burden on neglected tropical diseases publication-title: Lancet doi: 10.1016/S1473-3099(16)30328-0 – volume: 20 start-page: 12459 year: 2015 ident: ref_330 article-title: Anti-protozoal activities of cembrane-type diterpenes from Vietnamese soft corals publication-title: Molecules doi: 10.3390/molecules200712459 – ident: ref_13 doi: 10.3390/tropicalmed2030036 – volume: 86 start-page: 2607 year: 1989 ident: ref_73 article-title: Trypanothione is the primary target for arsenical drugs against African trypanosomes publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.86.8.2607 – volume: 90 start-page: S49 year: 2003 ident: ref_79 article-title: Eflornithine for the treatment of human African trypanosomiasis publication-title: Parasitol. Res. doi: 10.1007/s00436-002-0766-5 – volume: 278 start-page: 7206 year: 2003 ident: ref_184 article-title: Myristoyl-CoA: Protein N-myristoyltransferase, an essential enzyme and potential drug target in kinetoplastid parasites publication-title: J. Biol. Chem. doi: 10.1074/jbc.M211391200 – volume: 110 start-page: 363 year: 2015 ident: ref_36 article-title: Congenital Chagas disease: An update publication-title: Mem. Inst. Oswaldo Cruz doi: 10.1590/0074-02760140405 – ident: ref_223 doi: 10.1371/journal.pntd.0000252 – volume: 18 start-page: 93 year: 2019 ident: ref_138 article-title: The past, present and future of anti-malarial medicines publication-title: Malar. J. doi: 10.1186/s12936-019-2724-z – volume: 16 start-page: 531 year: 2017 ident: ref_170 article-title: Opportunities and challenges in phenotypic drug discovery: An industry perspective publication-title: Nat. Rev. Drug Discov. doi: 10.1038/nrd.2017.111 – ident: ref_4 doi: 10.3390/md17060329 – ident: ref_214 doi: 10.1371/journal.pntd.0007133 – volume: 389 start-page: 312 year: 2017 ident: ref_12 article-title: Neglected tropical diseases: Progress towards addressing the chronic pandemic publication-title: Lancet doi: 10.1016/S0140-6736(16)30171-4 – volume: 9 start-page: 3805 year: 2018 ident: ref_267 article-title: A high throughput screen for next-generation leads targeting malaria parasite transmission publication-title: Nat. Commun. doi: 10.1038/s41467-018-05777-2 – ident: ref_88 doi: 10.1371/journal.pntd.0000720 – volume: 17 start-page: 939 year: 2017 ident: ref_193 article-title: Trypanothione reductase: A target for the development of anti-Trypanosoma cruzi drugs publication-title: Mini Rev. Med. Chem. – volume: 11 start-page: 418 year: 2015 ident: ref_294 article-title: Antileishmanial activity of fucosterol recovered from Lessonia vadosa Searles (Lessoniaceae) by SFE, PSE and CPC publication-title: Phytochem. Lett. doi: 10.1016/j.phytol.2014.12.019 – volume: 71 start-page: 1148 year: 2016 ident: ref_271 article-title: A chemical susceptibility profile of the Plasmodium falciparum transmission stages by complementary cell-based gametocyte assays publication-title: J. Antimicrob. Chemother. doi: 10.1093/jac/dkv493 – volume: 11 start-page: 2107 year: 2019 ident: ref_190 article-title: Targeting pteridine reductase 1 and dihydrofolate reductase: The old is a new trend for leishmaniasis drug discovery publication-title: Future Med. Chem. doi: 10.4155/fmc-2018-0512 – volume: 13 start-page: 978 year: 2011 ident: ref_217 article-title: Quantitative proteome profiling informs on phenotypic traits that adapt Leishmania donovani for axenic and intracellular proliferation publication-title: Cell. Microbiol. doi: 10.1111/j.1462-5822.2011.01593.x – volume: 25 start-page: 110 year: 2018 ident: ref_158 article-title: Tafenoquine for travelers’ malaria: Evidence, rationale and recommendations publication-title: J. Travel. Med. doi: 10.1093/jtm/tay110 – ident: ref_44 doi: 10.1371/journal.pone.0035671 – volume: 22 start-page: 1 year: 2019 ident: ref_54 article-title: RTS,S/AS01 vaccine (Mosquirix™): An overview publication-title: Hum. Vaccin. Immunother. – volume: 18 start-page: 874 year: 2018 ident: ref_238 article-title: Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: A proof-of-concept, open-label, phase 2a study publication-title: Lancet Infect. Dis. doi: 10.1016/S1473-3099(18)30309-8 – volume: 10 start-page: 1853 year: 2018 ident: ref_236 article-title: Plasmodium falciparum dihydroorotate dehydrogenase: A drug target against malaria publication-title: Future Med. Chem. doi: 10.4155/fmc-2017-0250 – ident: ref_100 doi: 10.1371/journal.pntd.0002907 – ident: ref_18 – volume: 22 start-page: 6185 year: 2012 ident: ref_322 article-title: 2-Alkynoic fatty acids inhibit topoisomerase IB from Leishmania donovani publication-title: Bioorg. Med. Chem. Lett. doi: 10.1016/j.bmcl.2012.08.019 – volume: 34 start-page: 481 year: 2018 ident: ref_72 article-title: Melarsoprol resistance in African Trypanosomiasis publication-title: Trends Parasitol. doi: 10.1016/j.pt.2018.04.002 – volume: 39 start-page: e12431 year: 2017 ident: ref_114 article-title: Expression profiling of Sudanese visceral leishmaniasis patients pre- and post-treatment with sodium stibogluconate publication-title: Parasite Immunol. doi: 10.1111/pim.12431 – volume: 11 start-page: 106 year: 2019 ident: ref_112 article-title: Route map for the discovery and pre-clinical development of new drugs and treatments for cutaneous leishmaniasis publication-title: Int. J. Parasitol. Drugs Drug. Resist. doi: 10.1016/j.ijpddr.2019.06.003 – volume: 76 start-page: 485 year: 2016 ident: ref_122 article-title: Liposomal Amphotericin B (AmBisome®): A review of the pharmacokinetics, pharmacodynamics, clinical experience and future directions publication-title: Drugs doi: 10.1007/s40265-016-0538-7 – volume: 68 start-page: 2834 year: 2013 ident: ref_128 article-title: Immunomodulatory effects of antileishmanial drugs publication-title: J. Antimicrob. Chemother. doi: 10.1093/jac/dkt262 – volume: 560 start-page: 192 year: 2018 ident: ref_183 article-title: Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis publication-title: Nature doi: 10.1038/s41586-018-0356-z – volume: 55 start-page: 4512 year: 1990 ident: ref_9 article-title: Ecteinascidins 729, 743, 745, 759A, 759B, and 770: Potent antitumour agents from the Caribbean tunicate Ecteinascidia turbinata publication-title: J. Org. Chem. doi: 10.1021/jo00302a007 – volume: 12 start-page: 186 year: 2013 ident: ref_24 article-title: Clinical features, diagnosis, and treatment of human African trypanosomiasis (sleeping sickness) publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(12)70296-X – volume: 77 start-page: 435 year: 2017 ident: ref_5 article-title: Brentuximab Vedotin: A review in CD30-positive Hodgkin lymphoma publication-title: Drugs doi: 10.1007/s40265-017-0705-5 – volume: 271 start-page: 219 year: 1996 ident: ref_147 article-title: Plasmodium hemozoin formation mediated by histidine-rich proteins publication-title: Science doi: 10.1126/science.271.5246.219 – volume: 11 start-page: 3661 year: 2013 ident: ref_325 article-title: Synthesis of marine α-methoxylated fatty acid analogs that effectively inhibit the topoisomerase IB from Leishmania donovani with a mechanism different from that of camptothecin publication-title: Mar. Drugs doi: 10.3390/md11103661 – volume: 31 start-page: 411 year: 2003 ident: ref_177 article-title: Turnover of trypanosomal ornithine decarboxylases publication-title: Biochem. Soc. Trans. doi: 10.1042/bst0310411 – volume: 60 start-page: 2417 year: 2016 ident: ref_250 article-title: Assessment of the worldwide antimalarial resistance network standardized procedure for in vitro malaria drug sensitivity testing using SYBR green assay for field samples with various initial parasitemia levels publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.00527-15 – ident: ref_285 doi: 10.3390/md16080279 – volume: 338 start-page: 1557 year: 2005 ident: ref_309 article-title: DNA binding properties of 9-substituted harmine derivatives publication-title: Biochem. Biophys. Res. Commun. doi: 10.1016/j.bbrc.2005.10.121 – ident: ref_62 doi: 10.1371/journal.ppat.1005436 – volume: 205 start-page: 1278 year: 2012 ident: ref_277 article-title: Drug screen targeted at Plasmodium liver stages identifies a potent multistage antimalarial drug publication-title: J. Infect. Dis. doi: 10.1093/infdis/jis184 – volume: 44 start-page: 953 year: 2009 ident: ref_318 article-title: Total synthesis and antileishmanial activity of the natural occurring acetylenic fatty acids 6-heptadecynoic acid and 6-icosynoic acid publication-title: Lipids doi: 10.1007/s11745-009-3345-z – ident: ref_20 doi: 10.1371/journal.pntd.0006890 – volume: 14 start-page: 2317 year: 2009 ident: ref_113 article-title: Pentavalent antimonials: New perspectives for old drugs publication-title: Molecules doi: 10.3390/molecules14072317 – volume: 30 start-page: 210 year: 1981 ident: ref_82 article-title: Kinetics of alpha-difluoromethylornithine: An irreversible inhibitor of ornithine decarboxylase publication-title: Clin. Pharmacol. Ther. doi: 10.1038/clpt.1981.150 – volume: 49 start-page: 37 year: 2002 ident: ref_125 article-title: Amphotericin B nephrotoxicity publication-title: J. Antimicrob. Chemother. doi: 10.1093/jac/49.suppl_1.37 – volume: 34 start-page: 786 year: 2016 ident: ref_10 article-title: Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: Results of a phase III randomized multicenter clinical trial publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2015.62.4734 |
| SSID | ssj0035894 |
| Score | 2.4268417 |
| SecondaryResourceType | review_article |
| Snippet | Neglected Tropical Diseases (NTD) represent a serious threat to humans, especially for those living in poor or developing countries. Almost one-sixth of the... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 187 |
| SubjectTerms | Animals Antiprotozoal Agents - pharmacology Antiprotozoal Agents - therapeutic use Aquatic Organisms - chemistry Biological Products - pharmacology Biological Products - therapeutic use Drug Discovery Drug Resistance Euglenozoa Infections - drug therapy Euglenozoa Infections - parasitology high-throughput screening High-Throughput Screening Assays Humans malaria Malaria, Falciparum - drug therapy Malaria, Falciparum - parasitology Neglected Diseases - drug therapy Neglected Diseases - parasitology neglected tropical diseases phenotypic screening Plasmodium falciparum - drug effects Plasmodium malariae - drug effects Plasmodium malariae - pathogenicity Review target-based screening trypanosomatids Trypanosomatina - drug effects |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals (DOAJ) dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlp15K0-axaRMUEgKFmNqWLcnHJO2yBDYsdAN7M6OH04XgLevdw_77zFj7LIFccrWFLDQjzffhmW8Yu0yMAaQdEHmhfIQeIiKDwDgyIq4sGGfTthlM_0H2HrP7UT7aavVFOWFBHjhs3E9SyAKIZeGdzDC2QaWMkD5xRWbAtcXTKca8FZkKd7DIdZEFMVKBpB7JfaLRWxNKnNsKP61K_2vQ8v8Mya2Q0_3MPi2xIr8Ja9xnH3z9hV0Ngtj04poPN7VTzTW_4oONDPXiKxv9sZRTg6GJ94Fq_PgDtCIbfBBUXhuOgJXjLcd_TedPnJptNhyeYIyIkQ-nC7wnJs2EEC09rx1OgzR4DAfssft7eNeLln0UIosnbhYpB0Y5Q8wht5kvMMhrSo6olNKVTWyVI0XW0lYpGBsLLRHDWGHSOLfKSleIQ7ZXT2p_zHiVWgdWO4zzVERvC3DIH2OcW8auKnyH_Vhtb2mXIuPU6-K5RLJBpig3puiwi_XYf0Fa49VRt2Sl9QiSw24foJOUSycp33KSDjtf2bjE40P_RKD2k3lTImKRSBpTjWOOgs3Xn8K7LkP2qjtM7XjDzlp239Tjv61Et0Jmp2Vx8h6L_8Y-pkTy20LI72xvNp37U0RCM3PWOv0LdbcJEg priority: 102 providerName: Directory of Open Access Journals |
| Title | Screening Marine Natural Products for New Drug Leads against Trypanosomatids and Malaria |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/32244488 https://www.proquest.com/docview/2386287281 https://pubmed.ncbi.nlm.nih.gov/PMC7230869 https://doaj.org/article/5568aa069ed64910af7b36e1d94bad51 |
| Volume | 18 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Za9tAEB5yQMlL6V23jdnSEihERefu6qGEJk0IBRvT2uA3sZdcQ5BayYb633dGku04-Kmv0uhgZ0bzfdrdbwA-BlorpB3Kc5FwHkZI5GkExp6O_NwobU3YNIMZDPntJP4-TaYHsO7f2Q1gvZfaUT-pSXX3-e-f1QUm_BdinEjZkboHEmMxkOIQjrEiCepkMIg3swlRItO4lSZ9YH8CjzCgY6QocqcuNfL9-zDnw6WT92rRzRN43IFI9rX1-lM4cMUzOBu1KtSrczbebqqqz9kZG231qVfPYfrT0GIbrFlsoGjzHxuqRn2DjVr515ohkmX4-WPfquWMURfOmqmZmiOUZONqhR-Qsi4J6tLxwuJtcBDn6gVMbq7HV7de12DBM5iKC09YpYXVRCkSE7sUq7-kVRO5EDI3gckT5M6SmzxU2viR5AhuTKRDPzHCcJtGL-GoKAv3GlgeGquMtAgAaHe9SZVFYunjvblv89T14NN6eDPTqY9TE4y7DFkIeSXbeqUHHza2v1vNjb1Wl-SljQXpZDcHymqWdWmXkb6aUj5PneUxIiOVCx1xF9g01somQQ_er32cYV7RZIkqXLmsM4QyHNlkKNHmVevzzaPWMdMDsRMNO--ye6aY_2q0uwVSPsnTN_995Vs4CYnyN9si38HRolq6U8RFC92HQzEVfTi-vB6OfvSbvwv9JhH-AZoYEw8 |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Screening+Marine+Natural+Products+for+New+Drug+Leads+against+Trypanosomatids+and+Malaria&rft.jtitle=Marine+drugs&rft.au=%C3%81lvarez-Bard%C3%B3n%2C+Mar%C3%ADa&rft.au=P%C3%A9rez-Pertejo%2C+Yolanda&rft.au=Ord%C3%B3%C3%B1ez%2C+C%C3%A9sar&rft.au=Sep%C3%BAlveda-Crespo%2C+Daniel&rft.date=2020-03-31&rft.pub=MDPI&rft.eissn=1660-3397&rft.volume=18&rft.issue=4&rft_id=info:doi/10.3390%2Fmd18040187&rft_id=info%3Apmid%2F32244488&rft.externalDocID=PMC7230869 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1660-3397&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1660-3397&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1660-3397&client=summon |